SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended ~~March~~ 31September 30, 2024

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from_____________ to____________

Commission File Number: 0-56615

LONGDUODUO COMPANY LIMITED

(Exact name of registrant as specified in its charter)

Nevada		37-2018431
(State or other jurisdiction of		(I.R.S. Employer
incorporation or organization)		Identification Number)

G3-5-8016 Shui’an Town, Ruyi Headquarters Base

~~Ruyi Headquarters~~Hohhot ~~Base~~Economic Development Zone

~~Hohhot Economic~~Inner ~~Development~~Mongolia ~~Zone,~~010000

~~Inner Mongolia,~~P.R. ~~010000~~China

China

Office: +86 (0472) 510 4980

(Address, including zip code, and telephone number, including area code,

of Registrant’s principal executive offices)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class		Trading Symbol		Name of Each Exchange on Which Registered
None		None		Not Applicable

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☒
		Emerging growth company	☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12 b-2 of the Act). Yes ☐ No ☒

APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY

PROCEEDINGS DURING THE PRECEDING FIVE YEARS:

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐ No ☐

(APPLICABLE ONLY TO CORPORATE REGISTRANTS)

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.

As of the date of filing of this report, there were outstanding 30,005,016 shares of the issuer’s common stock, par value $0.001 per share.

TABLE OF CONTENTS

		Page
	PART I—FINANCIAL INFORMATION	1
Item 1	Financial Statements.	1
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2
Item 3.	Quantitative and Qualitative Disclosures About Market Risk.	75
Item 4.	Controls and Procedures.	75
	PART II—OTHER INFORMATION	86
Item 1.	Legal Proceedings.	86
Item 1A.	Risk Factors	86
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds.	86
Item 3.	Defaults Upon Senior Securities.	86
Item 4.	Mine Safety Disclosure	86
Item 5.	Other Information.	86
Item 6.	Exhibits.	96

PART I – FINANCIAL INFORMATION

Item 1. Financial Statements.

INDEX TO CONSOLIDATED FINANCIAL STATEMENTS

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

	Page
Consolidated Balance Sheets as of March 31, 2024 (Unaudited) and June 30, 2023	F-1
Consolidated Balance Sheets as of September 30, 2024 (Unaudited) and June 30, 2024	F-1
Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three and Nine Months Ended March 31, 2024 and 2023 (Unaudited)	F-2
Consolidated Statements of Operations and Comprehensive Income (Loss) for the Three Months Ended September 30, 2024 and 2023 (Unaudited)	F-2
Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the Three and Nine Months Ended March 31, 2024 and 2023 (Unaudited)	F-3
Consolidated Statements of Changes in Shareholders’ Equity (Deficit) for the Three Months Ended September 30, 2024 and 2023 (Unaudited)	F-3
Consolidated Statements of Cash Flows for the Nine Months Ended March 31, 2024 and 2023 (Unaudited)	F-4
Consolidated Statements of Cash Flows for the Three Months Ended September 30, 2024 and 2023 (Unaudited)	F-4
Notes to Consolidated Financial Statements (Unaudited)	F-5 – F-15

LONGDUODUO ~~COMPANY~~ COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED ~~BALANCE~~ BALANCE SHEETS

	March 31, 2024			June 30, 2023
	September 30, 2024			June 30, 2024
	(Unaudited)
Assets
Current Assets:
Cash and cash equivalents	$	1849,~~883,261~~840		$	1,~~136~~404,~~562~~042
Other receivables		~~107~~201,~~322~~248			~~107~~131,~~042~~376
Prepayments		~~225~~162,~~725~~593			68124,~~341~~427
Inventories		-			820
Total current assets		1,213,681			1,659,845
Total current assets		2,216,308			1,312,765
Property and equipment, net		392,409			353,486
Property and equipment, net		325,438			152,719
Right-of-use assets		47,354			50,070
Intangible asset, net		-			3,828
Total assets	$	1,653,444		$	2,063,401
Right-of-use assets		-			13,470
Liabilities and Equity
Total assets	$	2,541,746		$	1,482,782
Liabilities and Stockholders’ Equity (Deficit)
Current Liabilities:
Accounts payable	$	~~632~~168,~~610~~461		$	1358,~~044,247~~613
Deferred revenue		1608,~~135,696~~106			~~588~~713,~~335~~360
Accrued expenses		5141,~~220~~810			9050,~~858~~107
Due to related parties		2,~~245~~299			~~104~~2,~~611~~233
Security deposits		-			54,992
Other payables		25,682			35,660
Other payables		50,838			84,015
Operating lease liabilities, current		18,431			17,618
Operating lease liabilities, current		-			6,579
Other current liabilities		1,160			86,645
Other current liabilities		249,012			72,909
Total current liabilities		865,949			1,264,236
Total current liabilities		2,121,621			2,046,546
Operating lease liabilities, less current portion		19,159			18,314
Operating lease liabilities, less current portion		-			6,891
Total liabilities		885,108			1,282,550
Total liabilities		2,121,621			2,053,437
Equity (Deficit):
Stockholders’ Equity (Deficit):
Preferred stock; $0.001 par value, 30,000,000 shares authorized, no shares issued and outstanding at September 30, 2024 and June 30, 2024		-			-
Preferred stock; $0.001 par value, 30,000,000 shares authorized, no shares issued and outstanding at March 31, 2024 and June 30, 2023		-			-
Common stock; $0.001 par value, 500,000,000 shares authorized; 30,005,016 shares issued and outstanding at September 30, 2024 and June 30, 2024, respectively		30,005			30,005
Common stock; $0.001 par value, 500,000,000 shares authorized; 30,005,016 and 30,005,008 shares issued and outstanding at March 31, 2024 and June 30, 2023, respectively		30,005			30,005
Additional paid-in capital		7,246,729			7,246,729
Accumulated deficit		(6,~~940~~686,~~630~~935	)		(76,~~885~~629,~~080~~632	)
Accumulated other comprehensive income		6199,~~912~~627			6655,~~389~~413
Total stockholders’ equity (deficit) attributable to common stockholders		398,016			(541,957	)
Total stockholders’ equity		689,426			702,515
Non-controlling interests		2278,~~109~~910			~~(28~~78,~~698~~336	)
Total stockholders’ equity (deficit)		420,125			(570,655	)
Total stockholders’ equity attributable to the common stockholders		768,336			780,851
Total liabilities and equity(deficit)	$	2,541,746		$	1,482,782
Total liabilities and equity	$	1,653,444		$	2,063,401

The accompanying notes are an integral part of these consolidated financial statements.

F-1

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE ~~INCOME (~~ LOSS)

(UNAUDITED)

	For the Three Months Ended March 31,						For the Nine Months Ended March 31,
	For the Three Months Ended September 30,
	2024			2023			~~2024~~			~~2023~~
Revenues:
Service revenue	$	5346,~~807~~595		$	~~279~~171,~~457~~930		$	~~327,653~~		$	~~751,780~~
Product revenue		-			-			-			5,789
Commission revenue		722,477			1,415,503
Commission revenue		1,736,277			681			5,390,407			2,326
Total revenues, net		769,072			1,587,433
Total revenue, net		1,790,084			280,138			5,718,060			759,895
Cost of revenue:
Cost of revenue:
Cost of service revenue		32,276			62,351
Cost of service		38,597			118,516			143,347			299,603
Total cost of revenues		32,276			62,351
Cost of product		-			-			-			177
Gross profit		736,796			1,525,082
Total cost of revenues		38,597			118,516			143,347			299,780
Selling, general and administrative expenses		798,872			1,090,800
Gross profit		1,751,487			161,622			5,574,713			460,115
Income (loss) from operations		(62,076	)		434,282
Selling, general and administrative expenses		1,032,623			634,143			4,026,082			1,424,759
Other income (expense), net		2,752			1,362
Income (loss) from operations		718,864			(472,521	)		1,548,631			(964,644	)
Income (loss) before provision for income taxes		(59,324	)		435,644
Other income (expense), net		(9,603	)		1,213			(144,825	)		1,744
Provision for income taxes		180			140,900
Income (loss) before provision for income taxes		709,261			(471,308	)		1,403,806			(962,900	)
Net income (loss)		(59,504	)		294,744
Income tax expense		191,292			-			408,265			-
Less: net income (loss) attributable to non-controlling interests		(2,201	)		10,527
Net income (loss)		517,969			(471,308	)		995,541			(962,900	)
Net income (loss) attributable to common stockholders	$	(57,303	)	$	284,217
Less: net income (loss) attributable to non-controlling interests		6,425			(40,501	)		51,091			(94,522	)
Comprehensive income (loss):
Net income (loss) attributable to common stockholders	$	511,544		$	(430,807	)	$	944,450		$	(868,378	)
Net income (loss)	$	(59,504	)	$	294,744
Comprehensive income (loss):
Foreign currency translation adjustment		46,989			(1,148	)
Net income (loss)	$	517,969		$	(471,308	)	$	995,541		$	(962,900	)
Comprehensive income (loss)		(12,515	)		293,596
Foreign currency translation adjustment		(10,118	)		(7,394	)		(4,761	)		14,963
Less: comprehensive income (loss) attributable to non-controlling interests		574			10,598
Comprehensive income (loss)		507,851			(478,702	)		990,780			(947,937	)
Comprehensive income (loss) attributable to the common stockholders	$	(13,089	)	$	282,998
Less: comprehensive income (loss) attributable to non-controlling interests		6,344			(41,181	)		50,807			(93,109	)
Basic and diluted income (loss) per share	$	(0.002	)	$	0.01
Comprehensive income (loss) attributable to the common stockholders	$	501,507		$	(437,521	)	$	939,973		$	(854,828	)
Weighted average number of shares outstanding		30,005,016			30,005,008
Basic and diluted income (loss) per share	$	0.017		$	(0.014	)	$	0.031		$	(0.029	)
Weighted average number of shares outstanding-basic and diluted		30,005,016			30,000,008			30,005,016			30,000,008

The accompanying notes are an integral part of these consolidated financial statements.

F-2

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN ~~STOCKHOLDERS’~~ EQUITY (DEFICIT)

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~MARCH~~SEPTEMBER 3130, 2024 AND ~~MARCH~~SEPTEMBER 3130, 2023

(UNAUDITED)

	Common stock				Additional					Accumulated Other			Total			Non-
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Comprehensive ~~Loss~~Income			Stockholder’ Deficit			controlling ~~Interest~~Interests			Total Deficit
Balance at June 30, 2022		30,000,008	$	30,000	$	6,862,234	$	(7,845,991	)	$	24,971		$	(928,786	)	$	(93,553	)	$	(1,022,339	)
Balance at June 30, 2023		30,005,008	$	30,005	$	7,246,729	$	(7,885,080	)	$	66,389		$	(541,957	)	$	(28,698	)	$	(570,655	)
Net loss		-		-		-		(280,648	)		-			(280,648	)		(34,784	)		(315,432	)
Net income (loss)		-		-		-		284,217			-			284,217			10,527			294,744
Foreign currency translation adjustment		-		-		-		-			57(1,~~191~~219	)		57(1,~~191~~219	)		~~6,766~~71			63(1,~~957~~148	)
Balance at September 30, 2022		30,000,008		30,000		6,862,234		(8,126,639	)		82,162			(1,152,243	)		(121,571	)		(1,273,814	)
Balance at September 30, 2023		30,005,008	$	30,005	$	7,246,729	$	(7,600,863	)	$	65,170		$	(258,959	)	$	(18,100	)	$	(277,059	)
Net loss		-		-		-		(156,923	)		-			(156,923	)		(19,237	)		(176,160	)
Foreign currency translation adjustment		-		-		-		-			(36,927	)		(36,927	)		(4,673	)		(41,600	)
Balance at December 31, 2022		30,000,008	$	30,000	$	6,862,234	$	(8,283,562	)	$	45,235		$	(1,346,093	)	$	(145,481	)	$	(1,491,574	)
Net loss		-		-		-		(430,807	)		-			(430,807	)		(40,501	)		(471,308	)
Foreign currency translation adjustment		-		-		-		-			(6,714	)		(6,714	)		(680	)		(7,394	)
Balance at March 31, 2023		30,000,008	$	30,000	$	6,862,234	$	(8,714,369	)	$	38,521		$	(1,783,614	)	$	(186,662	)	$	(1,970,276	)

	Common stock				Additional					Accumulated Other			Total Stockholder’			Non-			Total
	Number of Shares		Amount		Paid-in Capital		Accumulated Deficit			Comprehensive Income			Equity (Deficit)			controlling Interests			Equity (Deficit)
Balance at June 30, 2023		30,005,008	$	30,005	$	7,246,729	$	(7,885,080	)	$	66,389		$	(541,957	)	$	(28,698	)	$	(570,655	)
Balance at June 30, 2024		30,005,016	$	30,005	$	7,246,729	$	(6,629,632	)	$	55,413		$	702,515		$	78,336		$	780,851
Net income (loss)		-		-		-		~~284~~(57,~~217~~303	)		-			~~284~~(57,~~217~~303	)		10(2,~~527~~201	)		~~294~~(59,~~744~~504	)
Foreign currency translation adjustment		-		-		-		-			(144,~~219~~214	)		(144,~~219~~214	)		712,775			(146,~~148~~989	)
Balance at September 30, 2023		30,005,008	$	30,005	$	7,246,729	$	(7,600,863	)	$	65,170		$	(258,959	)	$	(18,100	)	$	(277,059	)
Balance at September 30, 2024		30,005,016	$	30,005	$	7,246,729	$	(6,686,935	)	$	99,627		$	689,426		$	78,910		$	768,336
Adjustment for the reverse stock split		8		-		-		-			-			-			-			-
Net income (loss)		-		-		-		148,689			-			148,689			34,139			182,828
Foreign currency translation adjustment		-		-		-		-			6,779			6,779			(274	)		6,505
Balance at December 31, 2023		30,005,016	$	30,005	$	7,246,729	$	(7,452,174	)	$	71,949		$	(103,491	)	$	15,765		$	(87,726	)
Net income (loss)		-		-				511,544			-			511,544			6,425			517,969
Foreign currency translation adjustment		-		-				-			(10,037	)		(10,037	)		(81	)		(10,118	)
Balance at March 31, 2024		30,005,016	$	30,005	$	7,246,729	$	(6,940,630	)	$	61,912		$	398,016		$	22,109		$	420,125

The accompanying notes are an integral part of these consolidated financial statements

F-3

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the Nine Months Ended March 31,
	For the Three Months Ended September 30,
	2024			2023
Cash Flows from Operating Activities
Net income (loss)	$	~~995~~(59,~~541~~504	)	$	~~(962~~294,~~900~~744	)
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
Depreciation		7529,~~937~~998			5115,~~071~~516
Amortization		-			~~1,282~~-
Operating lease expense		3512,~~644~~463			572,~~687~~533
Loss on disposal of fixed assets		-			3,685
Changes in operating assets and liabilities:
Other receivables		217			10,776
Accounts receivable		-			(2,073	)
Prepayments		(192,880	)		(78,131	)
Other receivables		(63,809	)		(18,336	)
Inventories		832			848
Prepayments		(44,204	)		(219,754	)
Due from related parties		2,843			(9,758	)
Inventories		-			693
Accounts payable		(417,694	)		224,965
Due from related parties		44,390			(5,073	)
Deferred revenue		546,243			585,035
Accounts payable		(198,911	)		(303,001	)
Accrued expenses		(40,178	)		(26,813	)
Deferred revenue		(128,263	)		(98,675	)
Due to related parties		(105,225	)		374,589
Accrued expenses		(9,895	)		(22,989	)
Security deposits		(54,992	)		27,188
Due to related parties		(19,440	)		(75,333	)
Other payables		(34,084	)		260,836
Security deposits		-			4,773
Payment of operating lease liabilities		-			(21,633	)
Other payables		(11,031	)		(58,172	)
Other current liabilities		~~176~~(86,~~285~~792	)		1298,~~900~~293
Net cash provided by operating activities		988,489			507,942
Net cash used in operating activities		(534,998	)		(383,169	)
Cash Flows from Investing Activities
Purchase of property, plant and equipment		(~~248~~56,~~874~~431	)		(6920,~~584~~849	)
Purchase of intangible asset		-			(5,769	)
Net cash used in investing activities		(56,431	)		(20,849	)
Net cash used in investing activities		(248,874	)		(75,353	)
Cash Flows from Financing Activities
Repayment of short-term borrowing from third party		-			(138,450	)
Proceeds from short-term borrowing from third party		-			-
Net cash used in Financing Activities		-			(138,450	)
Net cash provided by financing activities		-			-
Effect of exchange rate fluctuation on cash and cash equivalents		737,~~084~~227			(62,~~189~~714	)
Net increase in cash and cash equivalents		746,699			287,950
Net increase (decrease) in cash and cash equivalents		(554,202	)		(406,732	)
Cash and cash equivalents, beginning of period		1,~~136~~404,~~562~~042			~~356~~1,~~672~~136,562
Cash and cash equivalents, end of period	$	1849,~~883,261~~840		$	~~644~~729,~~622~~830
Supplemental disclosure of cash flow information
Cash paid for income taxes	$	~~408,265~~180		$	-
Cash paid for interest expense	$	-		$	-

The accompanying notes are an integral part of these consolidated financial statements.

F-4

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~MARCH~~SEPTEMBER 3130, 2024 AND ~~MARCH~~SEPTEMBER 3130, 2023

(UNAUDITED)

NOTE 1. NATURE OF OPERATIONS AND BASIS OF PRESENTATION

Longduoduo Company Limited (“Longduoduo”, together as a group with Longduoduo’s subsidiaries referred to as the “Company” or “we”) was incorporated in the State of Nevada on October 25, 2021. ~~Initially~~Acting ~~acting~~ in a principal capacity, the Company ~~provided~~ provides customers comprehensive and high-quality preventive healthcare solutions including a wide range of preventive healthcare services, including disease screening healthcare treatment, healthcare products and other services through a network of third-party healthcare service providers. In June 2023, the Company began to engage in agent sales of preventive healthcare solutions on behalf of a third-party ~~providers~~ provider and earn commissions revenue.

On September 21, 2023, the Company implemented a 1-for-10 reverse split of its outstanding common stock, effective at the close of business on September 26, 2023. The accompanying financial statements have been adjusted to retroactively reflect this reverse stock split.

Longduoduo’s subsidiaries include:

●

Longduoduo Company Limited (Hong Kong) (“Longduoduo HK”), which was established on July 26, 2021 under the laws of Hong Kong. On October 26, 2021, Longduoduo issued 30,000,008 shares of its common stock to the original shareholders of Longduoduo HK, in exchange for 100% of the outstanding shares of Longduoduo HK (the “Share Exchange”).

●

Longduoduo Health Technology Company Limited (“Longduoduo Health Technology”), a privately held Limited Company registered in Inner Mongolia, China on August 20, 2020. On August 16, 2021, Longduoduo HK acquired 100% of the ownership of Longduoduo Health Technology from the original shareholders of Longduoduo Health Technology.

●

Inner Mongolia Qingguo Health Consulting Company Limited (“Qingguo”), a privately held Limited Company registered in Inner Mongolia, China on June 18, 2020. On September 8, 2020, Longduoduo Health Technology acquired 90% of the ownership of Qingguo from the original shareholders of Qingguo.

● Inner Mongolia Rongbin Health Consulting Company Limited (“Rongbin”), a privately held Limited Company registered in Inner Mongolia, China on March 18, 2021. Longduoduo Health Technology has controlled 80% of the ownership of Rongbin since ~~it was~~ established.

● Inner Mongolia Chengheng Health Consulting Company Limited (“Chengheng”), a privately held Limited Company registered in Inner Mongolia, China on April 9, 2021. Longduoduo Health Technology has controlled 80% of the ownership of Chengheng since ~~it was~~ established.

●

Inner Mongolia Tianju Health Consulting Company Limited (“Tianju”), a privately held Limited Company registered in Inner Mongolia, China on July 5, 2021. Longduoduo Health Technology has controlled 51% of Tianju since inception.

The transactions summarized above are treated in the Company’s financial statements as a corporate restructuring (reorganization) of entities under common control, as each of the seven entities ~~have~~has at all times been under the control of Mr. Zhang Liang. Therefore, in accordance with ASC 805-50-45-5, the current capital structure has been retroactively presented in prior periods as if such structure existed at that time, and the entities under common control are presented on a combined basis for all periods. Since all of the subsidiaries were under common control for all periods presented, the results of these subsidiaries are included in the Company’s financial statements for all periods presented.

F-5

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

FOR THE THREE ~~AND NINE~~ MONTHS ENDED ~~MARCH~~SEPTEMBER 3130, 2024 AND ~~MARCH~~SEPTEMBER 3130, 2023

(UNAUDITED)

NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Going concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and liquidation of liabilities in the normal course of business. At June 30, 2023, the Company had cash of $1,136,562, negative working capital of $733,781, and a stockholders’ deficit of $570,655. For the ~~years~~year ended June 30, 2023 ~~and June 30~~, ~~2022,~~ the Company had net income~~(loss)~~ of $21,085 ~~and $(7,563,565), respectively~~. The Company’s independent auditor included a going concern emphasis paragraph in its audit report for the years ended June 30, 2023 and June 30, 2022.

Commencing in the last quarter of the fiscal year ended June 30, 2023, the Company changed its business plan to focus on resale of health care services offered by its contractor. The benefits of the change were promptly realized. At ~~March~~June 3130, 2024, the Company had cash of $ 1,~~883~~404,~~261~~042, working capital of $94395,~~687~~609, and stockholders’ equity of $~~420~~780,~~125~~851. For the ~~nine~~years ~~months~~ ended ~~March~~June 3130, 2024, the Company had net income of $~~995~~1,~~541~~363,278. As a result of the improved results, the Company’s independent auditor did not include a going concern emphasis paragraph in its audit report for the year ended June 30, 2024. Although we cannot guarantee that we will continue to achieve profits in our operations, the initial results of the change in our business plan have reduced our doubts concerning the ability of the Company to continue as a going concern.

B. ~~Basis~~ Basis of presentation

The ~~accompanying~~ accompanying consolidated financial statements are expressed in U.S. Dollars and have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

~~Interim~~C. Principles ~~Financial~~of ~~Information~~consolidation

The ~~unaudited~~ consolidated financial statements ~~have~~include ~~been prepared in accordance with generally accepted accounting principles (GAAP) applicable to interim financial information and~~ the ~~requirements~~accounts of ~~Form~~Longduoduo ~~10-Q~~ and ~~Rule~~its ~~8-03~~subsidiaries. ofAll ~~Regulation~~significant Sinter-Xcompany ofaccounts ~~the Securities~~ and ~~Exchange Commission. Accordingly,~~transactions they do not include all of the information and disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Interim results are not necessarily indicative of results for a full year. In the opinion of management, all adjustments considered necessary for a fair presentation of the financial position and the results of operations and cash flows for the interim periods have been ~~included~~eliminated. ~~These~~The consolidated financial statements ~~should~~include 100% ~~be read in conjunction with the audited financial statements as~~ of ~~and for the year ended June 30~~assets, ~~2023~~liabilities, ~~as not all disclosures required by generally accepted accounting principles for annual financial statements are presented. The interim financial statements follow the same accounting policies~~ and ~~methods~~net ofincome ~~computations as~~or ~~the~~loss ~~audited financial statements as~~ of ~~and for the year ended June 30, 2023~~these subsidiaries.

C.Longduoduo’s ~~Principles~~subsidiaries as of ~~consolidation~~September 30, 2024 are listed as follows:

The consolidated financial statements include the accounts of Longduoduo and its subsidiaries. All significant inter-company accounts and transactions have been eliminated. The consolidated financial statements include 100% of assets, liabilities, and net income or loss of these subsidiaries.

Name	Place of Incorporation	Attributable equity interest %		Authorized capital
Longduoduo Company Limited	Hong Kong		100	HK$	10,000
Longduoduo Health Technology Company Limited	China		100		0
Inner Mongolia Qingguo Health Consulting Company Limited	China		90		0
Inner Mongolia Rongbin Health Consulting Company Limited	China		80		0
Inner Mongolia Chengheng Health Consulting Company Limited	China		80		0
Inner Mongolia Tianju Health Consulting Company Limited	China		51		0

~~Longduoduo’s subsidiaries~~D. as Use of ~~March 31, 2024 are listed as follows:~~estimates

Name	Place of Incorporation	Attributable equity interest %		Authorized capital
Longduoduo Company Limited	Hong Kong		100	HK$	10,000
Longduoduo Health Technology Company Limited	China		100		0
Inner Mongolia Qingguo Health Consulting Company Limited	China		90		0
Inner Mongolia Rongbin Health Consulting Company Limited	China		80		0
Inner Mongolia Chengheng Health Consulting Company Limited	China		80		0
Inner Mongolia Tianju Health Consulting Company Limited	China		51		0

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the inventory valuation allowance and the treatment of the shares issued. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.

~~D. Use of estimates~~F-6

~~The preparation~~LONGDUODUO ofCOMPANY ~~consolidated~~LIMITED ~~financial~~AND statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting periods. Management makes these estimates using the best information available at the time the estimates are made; however, actual results could differ from those estimates. Significant items subject to such estimates and assumptions include the inventory valuation allowance and the treatment of the shares issued. These estimates are often based on complex judgments and assumptions that management believes to be reasonable but are inherently uncertain and unpredictable. Actual results could differ from these estimates.SUBSIDIARIES

~~F-6~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~LONGDUODUO COMPANY~~FOR ~~LIMITED~~THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND ~~SUBSIDIARIES~~SEPTEMBER 30, 2023

~~NOTES TO CONSOLIDATED FINANCIAL STATEMENTS~~(UNAUDITED)

~~FOR~~E. Functional ~~THE~~currency ~~THREE~~and ~~AND~~foreign ~~NINE~~currency ~~MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023~~translation

An entity’s functional currency is the currency of the primary economic environment in which it operates, normally that is the currency of the environment in which the entity primarily generates and expends cash. Management’s judgment is essential to determine the functional currency by assessing various indicators, such as cash flows, sales price and market, expenses, financing and inter-company transactions and arrangements. The functional currency of the Company is the Chinese Renminbi (~~UNAUDITED~~“RMB’), except the functional currency of Longduoduo HK is the Hong Kong Dollar and the functional currency of Longduoduo is the United States Dollar (“US Dollars” or “$”). The reporting currency of these consolidated financial statements is in US Dollars.

E.The financial statements of Longduoduo’s ~~Functional~~subsidiaries, which are prepared using the RMB, are translated into the Company’s reporting currency, the US Dollar. Assets and liabilities ~~foreign~~are ~~currency~~translated using the exchange rate at each reporting period end date. Revenue and expenses are translated using weighted average rates prevailing during each reporting period, and stockholders’ equity (deficit) is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income or expense.

~~An entity’s~~Transactions ~~functional~~denominated ~~currency is the currency of the primary economic environment~~ in ~~which~~currencies itother ~~operates. Normally that is the currency~~than of the ~~environment in which the entity primarily generates and expends cash. Management’s judgment is essential to determine the~~ functional currency byare ~~assessing~~translated ~~various~~into ~~indicators,~~the ~~such as cash flows, sales price and market, expenses, financing and inter-company transactions and arrangements. The~~ functional currency ofat the ~~Company~~exchange isrates ~~the~~prevailing ~~Chinese~~at ~~Renminbi (“RMB’), except~~ the ~~functional currency~~dates of ~~Longduoduo HK is~~ the ~~Hong~~transactions. Foreign ~~Kong Dollar and the functional~~ currency ofexchange ~~Longduoduo~~gains isand ~~the~~losses ~~United~~resulting ~~States~~from ~~Dollar (“US Dollars” or “$”). The reporting currency of~~ these ~~consolidated~~transactions ~~financial~~are ~~statements~~included is in ~~US Dollars~~operations.

The financial statements of Longduoduo’s subsidiaries, which are prepared using the RMB, are translated into the Company’s reporting currency, the US Dollar. Assets and liabilities are translated using the exchange rate at each reporting period end date. Revenue and expenses are translated using weighted average rates prevailing during each reporting period, and stockholders’ equity (deficit) is translated at historical exchange rates. Adjustments resulting from the translation are recorded as a separate component of accumulated other comprehensive income or expense.

		For the Three Months Ended September 30,
		2024		2023
		(RMB/HKD to USD)		(RMB/HKD to USD)
Assets and liabilities	period end exchange rate		7.0149/7.7702		7.2952/7.8314
Revenue and expenses	period weighted average		7.1614/7.7992		7.2364/7.8243

~~Transactions denominated~~F. inConcentration ~~currencies other than the functional currency are translated into the functional currency at the exchange rates prevailing at the dates~~ of ~~the~~credit ~~transactions. Foreign currency exchange gains and losses resulting from these transactions are included in operations.~~risk

The Company ~~exchange~~maintains ~~rates~~cash ~~used~~in ~~for~~state-owned ~~foreign~~banks ~~currency~~in ~~translation~~China. ~~are~~In asChina, ~~follows:~~the insurance coverage of each bank is RMB500,000 (approximately USD$71,000). As of September 30, 2024 and June 30, 2024, the Company had $361,360 and $826,853 cash in excess of the insured amount, respectively.

		For the Nine Months Ended March 31,
		2024		2023
		(USD to RMB/ USD to HKD)		(USD to RMB/ USD to HKD)
Assets and liabilities	period end exchange rate		7.2221/7.8253		6.8680/7.8498
Revenue and expenses	period weighted average		7.2008/7.8195		6.9339/7.8362

For each of the three months ended September 30, 2024 and 2023, one customer accounted for 99.9% of commission revenue.

F.For the three months ended September ~~Concentration~~30, 2024 and 2023, the Company had three major suppliers that each accounted for over 10% of ~~credit~~its ~~risk~~total cost of revenue.

The Company maintains cash in state-owned banks in China. In China, the insurance coverage of each bank is RMB500,000 (approximately USD$69,000). As of March 31, 2024 and June 30, 2023, the Company had $1,170,932 and $606,483 cash in excess of the insured amount, respectively.

	For the Three Months Ended September 30, 2024					For the Three Months Ended September 30, 2023
	Cost of revenue		Percentage of Cost of revenue			Cost of revenue		Percentage of Cost of revenue

Supplier A	$	13,167		43	%	$	20,406		33	%
Supplier B		11,429		37	%		19,032		31	%
Supplier C		4,031		13	%		15,141		24	%

~~For the nine months ended March 31, 2024, 94~~G.3 ~~% of commission revenue was attributable to the Company’s introduction of customers~~Cash toand acash ~~single service provider. For the nine months ended March 31, 2023, no customer accounted for more than 10% of revenue.~~equivalents

~~For~~Cash consists ~~the~~of ~~nine~~cash ~~months~~on ~~ended~~hand ~~March~~and 31bank deposits, ~~2024~~which are unrestricted as to withdrawal and ~~2023,~~use. ~~the~~All highly liquid investments with original stated maturity of three months or less are classified as cash and cash equivalents. Cash equivalents approximate or equal fair value due to their short-term nature. The Company’s ~~had~~cash ~~four~~and ~~major~~cash ~~suppliers~~equivalents ~~that~~consist ~~accounted~~of ~~for~~cash ~~over 10%~~on hand and cash in bank as of ~~its~~September ~~total~~30, ~~cost~~2024 ofand ~~revenue~~June 30, 2024.

	For the Nine Months Ended March 31,
	2024					2023
	Cost of revenue		Percentage of Cost of revenue			Cost of revenue		Percentage of Cost of revenue
Supplier A	$	29,454		21	%	$	110,993		37	%
Supplier B		51,302		36	%		57,587		19	%
Supplier C		43,478		30	%		53,500		18	%
Supplier D		8,278		6	%		45,009		15	%

F-7

~~G. Cash~~LONGDUODUO ~~and~~COMPANY ~~cash~~LIMITED ~~equivalents~~AND SUBSIDIARIES

~~Cash consists~~NOTES ofTO ~~cash~~CONSOLIDATED onFINANCIAL hand and bank deposits, which are unrestricted as to withdrawal and use. All highly liquid investments with original stated maturity of three months or less are classified as cash and cash equivalents. Cash equivalents approximate or equal fair value due to their short-term nature. The Company’s cash and cash equivalents consist of cash on hand and cash in banks as of March 31, 2024 and June 30, 2023.STATEMENTS

~~F-7~~FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND SEPTEMBER 30, 2023

~~LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES~~(UNAUDITED)

~~NOTES TO~~H. ~~CONSOLIDATED~~Property ~~FINANCIAL~~and ~~STATEMENTS~~equipment

~~FOR~~Property and equipment are stated at cost. Expenditures ~~THE~~for ~~THREE~~maintenance ~~AND~~and ~~NINE~~repairs ~~MONTHS~~are ~~ENDED~~charged ~~MARCH~~to 31operations when incurred, ~~2024~~while ~~AND~~additions ~~MARCH~~and 31betterments are capitalized. Depreciation is recorded on a straight-line basis over the useful lives of the assets. When assets are retired or disposed, ~~2023~~the asset’s original cost and related accumulated depreciation are eliminated from those accounts and any gain or loss is reflected in income.

~~(UNAUDITED)~~The Company capitalizes certain costs associated with the acquisition of software. Once the software is ready for its intended use, these costs are amortized on a straight-line basis over the software’s expected useful life.

~~H. Property~~The estimated useful lives for property and equipment categories are as follows:

Property and equipment are stated at cost. Expenditures for maintenance and repairs are charged to operations when incurred, while additions and betterments are capitalized. Depreciation is recorded on a straight-line basis over the useful lives of the assets. When assets are retired or disposed, the asset’s original cost and related accumulated depreciation are eliminated from those accounts and any gain or loss is reflected in income.

Office equipment and furniture		3 years
Leasehold Improvements		1-5 years

~~The estimated~~I. ~~useful~~Intangible ~~lives for property and equipment categories are as follows:~~Assets

Office equipment and furniture		3-5 years
Leasehold Improvements		1-5 years

Intangible assets consist of software. Intangible assets are initially recognized at their respective acquisition costs. All of the Company’s intangible assets have been determined to have finite useful lives and are, therefore, amortized using the straight-line method over their estimated useful lives:

~~I. Intangible~~Software ~~Assets~~3 years

~~Intangible assets consist of software~~J. ~~Intangible~~Fair ~~assets~~value are initially recognized at their respective acquisition costs. All of the Company’s intangible assets have been determined to have finite useful lives and were, therefore, amortized using the straight-line method over their estimated useful lives:measurements

~~Software~~The 3Company ~~years~~applies the provisions of the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Section 820, Fair Value Measurements (“ASC 820”), for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements. ASC 820 also establishes a framework for measuring fair value and expands disclosures about fair value measurements.

J. Fair value ~~measurements~~is defined as the price that would be received when selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining the fair value for the assets and liabilities required or permitted to be recorded, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.

~~The~~ASC 820 establishes a fair value hierarchy that ~~Company~~requires ~~applies~~an ~~the~~entity ~~provisions~~to ofmaximize the ~~Financial~~use ~~Accounting~~of ~~Standards~~observable ~~Board~~inputs ~~(“FASB”)~~and ~~Accounting~~minimize ~~Standards~~the ~~Codification~~use ~~(“ASC”) Section~~of ~~820, Fair~~unobservable ~~Value~~inputs ~~Measurements (“ASC~~when ~~820”),~~measuring ~~for~~ fair value. ~~measurements~~ASC 820 establishes three levels of ~~financial~~inputs ~~assets~~that ~~and~~may ~~financial liabilities~~be ~~and~~used ~~for~~to measure fair value. ~~measurements~~The ofhierarchy ~~nonfinancial~~gives ~~items~~the ~~that~~highest ~~are~~priority ~~recognized~~to unadjusted quoted prices in active markets for identical assets or ~~disclosed~~liabilities at(Level ~~fair~~1 ~~value~~measurements) inand the ~~financial~~lowest ~~statements. ASC~~priority ~~820~~to ~~also~~measurements ~~establishes~~involving significant aunobservable ~~framework~~inputs ~~for~~(Level ~~measuring~~3 ~~fair~~measurements). ~~value~~The ~~and~~three ~~expands~~levels ~~disclosures~~of ~~about~~the fair value ~~measurements.~~hierarchy are as follows:

~~Fair value~~Level is1: ~~defined~~Unadjusted asquoted ~~the~~prices ~~price that would be received when selling an asset or paid to transfer a liability~~ in anactive ~~orderly transaction~~markets ~~between~~that ~~market~~are ~~participants~~accessible at the measurement date. ~~In determining the fair value~~ for ~~the assets and liabilities required or permitted to be recorded~~identical, ~~the~~unrestricted ~~Company~~assets ~~considers the principal~~ or ~~most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.~~liabilities;

~~ASC 820~~Level ~~establishes~~2: aQuoted ~~fair~~prices, ~~value~~other ~~hierarchy~~than ~~that~~those ~~requires~~in ~~an entity to maximize the use of observable inputs and minimize the use of unobservable~~Level ~~inputs~~1, ~~when~~in ~~measuring~~markets ~~fair~~that ~~value.~~are ~~ASC~~not ~~820~~active, ~~establishes~~or ~~three levels of~~ inputs that ~~may~~are beobservable, ~~used~~either todirectly ~~measure~~or ~~fair~~indirectly, ~~value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets~~ for ~~identical~~substantially ~~assets or liabilities (Level 1 measurements) and~~ the ~~lowest~~ ~~priority~~full toterm ~~measurements involving significant unobservable inputs (Level 3 measurements). The three levels~~ of the ~~fair value~~ ~~hierarchy~~asset ~~are~~or ~~as follows:~~liability,

Level 1 3: ~~Unadjusted~~Prices ~~quoted~~or ~~prices~~valuation intechniques ~~active~~that ~~markets~~require inputs that are ~~accessible~~both atsignificant to the fair value measurement ~~date~~and ~~for~~unobservable ~~identical,~~(supported ~~unrestricted~~by ~~assets~~little or ~~liabilities;~~no market activity).

~~Level 2:~~There ~~Quoted~~were ~~prices,~~no ~~other~~transfers ~~than~~between ~~those~~level ~~in Level~~ 1, inlevel 2 ~~markets that are not active,~~ or ~~inputs~~level ~~that~~3 ~~are~~measurements ~~observable, either directly or indirectly,~~ for ~~substantially~~ the ~~full~~years ~~term~~ended ofJune ~~the~~30, ~~asset~~2024 orand ~~liability,~~2023.

~~Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (supported by little or no market activity).~~F-8

~~There were~~LONGDUODUO noCOMPANY ~~transfers~~LIMITED ~~between~~AND ~~level 1, level 2 or level 3 measurements for the nine months ended March 31, 2024 and 2023.~~SUBSIDIARIES

~~Financial assets~~NOTES ~~and~~TO ~~liabilities~~CONSOLIDATED ofFINANCIAL the Company are primarily comprised of cash and cash equivalents, other receivables, accounts payable, accrued expenses, due to related parties, security deposits and other payables. As of March 31, 2024 and June 30, 2023, the carrying values of these financial instruments approximated their fair values due to the short-term maturity of these instruments.STATEMENTS

~~F-8~~FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 AND SEPTEMBER 30, 2023

~~LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES~~(UNAUDITED)

~~NOTES~~Financial assets and liabilities of the Company TOare ~~CONSOLIDATED~~primarily ~~FINANCIAL~~comprised ~~STATEMENTS~~of cash and cash equivalents, other receivables, accounts payable, accrued expenses, due to related parties, loan from third party, security deposits and other payables. As of June 30, 2024 and 2023, the carrying values of these financial instruments approximated their fair values due to the short-term maturity of these instruments.

~~FOR THE~~K. ~~THREE~~Segment ~~AND~~information ~~NINE~~and ~~MONTHS~~geographic ~~ENDED MARCH 31, 2024 AND MARCH 31, 2023~~data

The Company is operating in one segment in accordance with the accounting guidance in FASB ASC Topic 280, Segment Reporting. The company’s revenues are from customers in the People’s Republic of China (~~UNAUDITED~~“PRC”). Substantially all assets of the Company are located in the PRC.

KL. ~~Segment~~ ~~information~~Revenue ~~and geographic data~~recognition

The Company isadopted ~~operating~~FASB inASC ~~one~~Section ~~segment~~606 in— Revenue ~~accordance~~from Contracts with Customers. Under ASC 606, the ~~accounting~~Company ~~guidance~~recognizes inrevenue ~~FASB~~from ~~ASC~~the ~~Topic~~sales ~~280, Segment~~of ~~Reporting. The~~products ~~company’s~~and ~~revenues~~services ~~are~~by ~~from~~applying the ~~customers~~following insteps: (1) identify the ~~People’s~~contract ~~Republic~~with ofa ~~China~~customer; (~~“PRC”~~2). ~~Substantially~~identify ~~all~~the ~~assets~~performance obligations in the contract; (3) determine ofthe transaction price; (4) allocate the ~~Company~~transaction ~~are~~price ~~located~~to each performance obligation in the ~~PRC~~contract; and (5) recognize revenue when each performance obligation is satisfied.

L.The Company recognizes revenue when the amount ~~Revenue~~of ~~recognition~~revenue can be reliably measured, it is probable that economic benefits will flow to the entity, and specific criteria have been met for each of the Company’s activities as described below.

~~The Company~~Service ~~adopted FASB ASC Section 606 —~~ Revenue from Contracts with Customers. Under ASC 606, the Company recognizes revenue from the sales of products and services by applying the following steps: (1) identify the contract with a customer; (2) identify the performance obligations in the contract; (3) determine the transaction price; (4) allocate the transaction price to each performance obligation in the contract; and (5) recognize revenue when each performance obligation is satisfied.

The Company ~~recognizes~~sells ~~revenue~~healthcare ~~when~~service packages to customers, which represent the ~~amount~~rights to services purchased by the Company. The delivery of ~~revenue~~a ~~can~~healthcare beservice ~~reliably~~package ~~measured,~~to ita iscustomer represents ~~probable~~a ~~that~~separate ~~economic~~performance ~~benefits~~obligation. ~~will~~The ~~flow~~Company’s policy is to recognize service revenue at that time when the healthcare ~~entity~~service package has been sold, ownership and ~~specific~~risk ~~criteria~~of loss have been ~~met~~transferred ~~for~~to ~~each~~the ofcustomer, and the ~~Company’s~~service ~~activities~~has asbeen ~~described~~provided. ~~below~~Accordingly, revenue is recognized at the point in time when the service is provided. Service revenue is recognized when the healthcare service package has been delivered to the customer and there are no remaining performance obligations.

~~Service~~Management regularly reviews the sales returns and ~~Product~~allowances ~~Revenue~~based on historical experience. Any subsequent sales returns and cancellations are recognized upon notification from the customers. The liability for sales returns and allowances relating to the sale of healthcare service packages amounted to $899 and $923 as of September 30, 2024 and June 30, 2024, respectively. Management’s provision for sales returns and allowances was 1.39% and 1.13%, respectively, of the total service revenue for the three months ended September 30, 2024 and 2023

The Company ~~sells~~typically ~~healthcare~~collects ~~packages,~~fees ~~including~~before ~~healthcare~~delivery of ~~consulting services and~~ healthcare ~~products~~packages. ~~Customers~~Amounts ~~may~~received ~~purchase~~from a ~~healthcare services~~customer ~~package,~~before orthe ~~healthcare~~delivery ~~services combined with nutritional products. Currently all sales~~ of ~~products~~the ~~are bundled with~~ healthcare ~~services.~~ ~~The~~package ~~combination of services and products~~ are ~~generally~~recorded ~~capable of being distinct and accounted for~~ as ~~separate~~deferred ~~performance~~revenue ~~obligations.~~on ~~For~~ the ~~sale~~Consolidated ofBalance ~~healthcare packages that include services and products, the Company allocates revenues based on their relative selling prices~~Sheets.

~~The~~Commission Company sells a healthcare service package to a customer, which represents the rights to services purchased by the Company. The delivery of a healthcare service package to a customer represents a separate performance obligation. The Company’s policy is to recognize service revenue at that time when the healthcare service package has been sold, ownership and risk of loss have been transferred to the customer, and the service has been provided. Accordingly, revenue is recognized at the point in time when the service is provided. Service revenue is recognized when the healthcare service package has been delivered to the customer and there are no remaining performance obligations.Revenue

~~Management regularly~~Commencing ~~reviews~~in the ~~sales~~three ~~returns~~months ~~and~~ended ~~allowances~~June ~~based~~30, 2023, onthe ~~historical~~Company ~~experience.~~started ~~Any~~offering ~~subsequent~~in a sales ~~returns~~agent ~~and~~capacity ~~cancellations~~healthcare ~~are recognized~~service ~~upon~~and ~~notification~~product ~~from~~packages ~~the~~of ~~customers~~a third-party provider. The ~~liability~~third party ~~for~~is ~~sales~~responsible ~~returns~~for ~~and~~fulfillment ~~allowances~~of ~~relating~~the services to the ~~sale~~customer ofand ~~healthcare~~the ~~service packages~~Company ~~amounted~~has no performance commitment or liability to ~~$891 and~~the customer. ~~$15,406 as~~The ofCompany ~~March~~receives 31deposits from the customers, ~~2024~~remits ~~and~~to ~~June~~the ~~30,~~third-party ~~2023,~~provider ~~respectively.~~the ~~Management~~provider’s ~~provision~~contracted ~~for~~amounts, ~~sales~~and ~~returns~~retains ~~and~~the ~~allowances~~remaining ~~was 1.14%~~amounts ~~and 1~~as commission revenue.~~3%,~~ ~~respectively,~~The commission revenue is recognized upon acceptance of the ~~total~~customer ~~service~~contract by ~~revenue~~the ~~for~~third-party ~~the~~provider ~~nine~~and ~~months~~is ~~ended~~presented ~~March 31,~~on ~~2024~~a net basis in the Statement of Operations and ~~March~~Comprehensive ~~31,~~Income ~~2023~~(Loss).

~~Product revenue~~Cost ~~results from the sale~~ of healthcare and nutritional products, including Collagen peptide, Calcium tablets and other products. The Company recognizes revenue when the product has been delivered and ownership and risk of loss have been transferred to the customer. The Company accepts returns provided the products are well packaged and can be resold. Management regularly reviews the sales returns and allowances based on historical experience. The liability for sales returns and allowances relating to the sale of healthcare products amounted to $0 and $229 as of March 31, 2024 and June 30, 2023, respectively. Management’s provision for sales returns and allowances was 0% and 1.77%, respectively, of the total product revenue for the nine months ended March 31, 2024 and March 31, 2023.Revenues

~~The Company~~Cost ~~typically~~of ~~collects~~service ~~fees~~revenue ~~before~~consists ~~delivery~~primarily of the cost of healthcare service packages. ~~Amounts~~purchased ~~received~~ from athird ~~customer~~party ~~before the delivery of the~~ healthcare ~~package~~ ~~are~~service ~~recorded~~providers asto ~~deferred~~fulfill ~~revenue~~contracts onwith ~~the Consolidated Balance Sheets~~customers.

~~Commission~~Cost of product revenue consists primarily of ~~Revenue~~the cost of healthcare products purchased from suppliers. Cost of product revenue is recognized when the product has been delivered to the customer.

~~Commencing in the three months ended June 30, 2023, the Company started offering in a sales agent capacity healthcare service and product packages of a third~~F-party provider. The third party is responsible for fulfillment of the services to the customer and the Company has no performance commitment or liability to the customer. The Company receives deposits from the customers, remits to the third-party provider the provider’s contracted amounts, and retains the remaining amounts as commission revenue. The commission revenue is recognized upon acceptance of the customer contract by the third-party provider and is presented on a net basis in the Statements of Operations and Comprehensive Income (Loss).9

~~Cost of~~LONGDUODUO ~~Revenues~~COMPANY LIMITED AND SUBSIDIARIES

~~Cost of~~NOTES ~~service~~TO ~~revenue~~CONSOLIDATED ~~consists~~FINANCIAL ~~primarily of the cost of healthcare service packages purchased from third party healthcare service providers to fulfill contracts with customers.~~STATEMENTS

~~Cost of~~FOR ~~product~~THE ~~revenue~~THREE ~~consists~~MONTHS ~~primarily~~ENDED ofSEPTEMBER ~~the~~30, ~~cost of healthcare products purchased from suppliers. Cost of product revenue is recognized~~2024 ~~when~~AND ~~the~~SEPTEMBER ~~product~~30, ~~has been delivered to the customer.~~2023

~~F-9~~(UNAUDITED)

~~LONGDUODUO COMPANY~~M. ~~LIMITED AND SUBSIDIARIES~~Income taxes

~~NOTES~~The Company follows FASB ASC Section 740, Income TOTaxes, ~~CONSOLIDATED~~which ~~FINANCIAL~~requires ~~STATEMENTS~~the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements or tax returns. Under this method, deferred income taxes are recognized for the tax consequences in future years of differences between the tax bases of assets and liabilities and their financial reporting amounts at each period end based on enacted tax laws and statutory tax rates applicable to the periods in which the differences are expected to affect taxable income. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized.

~~FOR~~ASC 740-10-30 requires income tax positions to ~~THE~~meet ~~THREE~~a ~~AND~~more-likely-than-not ~~NINE~~recognition ~~MONTHS~~threshold ~~ENDED~~to ~~MARCH~~be ~~31,~~recognized ~~2024~~in ~~AND~~the ~~MARCH~~financial 31statements. Under ASC 740-10-30, ~~2023~~tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first subsequent financial reporting period in which that threshold is met.

~~(UNAUDITED)~~The application of tax laws and regulations is subject to legal and factual interpretation, judgment and uncertainty. Tax laws and regulations themselves are subject to change as a result of changes in fiscal policy, changes in legislation, the evolution of regulations and court rulings. Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or the deferred tax asset valuation allowance.

M.As a result of the implementation of ASC 740-10, ~~Advertising~~the ~~and~~Company ~~promotion~~made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10. The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation.

~~Advertising and~~N. ~~promotion~~Earnings ~~costs,~~(loss) ~~which~~per ~~are expensed as incurred, were $2,667,233 and $539,836 for the nine months ended March 31, 2024 and March 31, 2023, respectively.~~share

NThe Company computes earnings (loss) per share (“EPS”) in accordance with ASC 260, Earnings Per Share. ASC 260 requires companies with complex capital structures ~~Income~~to ~~taxes~~present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average common shares outstanding during the period.

~~The Company~~Diluted ~~follows~~EPS ~~FASB~~is ~~ASC~~similar ~~Section~~to ~~740, Income~~basic ~~Taxes,~~EPS ~~which~~but ~~requires~~ presents the ~~recognition~~dilutive effect on a per share basis of ~~deferred~~contracts ~~tax~~to ~~assets~~issue ~~and~~common ~~liabilities for~~shares ~~the~~(e.g., ~~expected~~convertible ~~future~~securities, ~~tax~~options ~~consequences~~and ofwarrants) ~~events~~as ~~that~~if they ~~have~~had been ~~included~~converted inat the ~~financial~~beginning ~~statements~~of orthe ~~tax~~periods ~~returns.~~presented, ~~Under~~or ~~this~~issuance ~~method~~date, ~~deferred~~ ~~income~~if ~~taxes~~later. ~~are~~The ~~recognized~~computation ~~for~~of diluted EPS includes the ~~tax~~estimated ~~consequences~~impact inof ~~future~~the ~~years~~exercise of ~~differences~~contracts ~~between~~to ~~the~~purchase ~~tax~~common ~~bases~~stock ofusing ~~assets~~the ~~and~~treasury ~~liabilities~~ stock method and ~~their~~the ~~financial~~potential ~~reporting~~shares ~~amounts~~of converted atcommon ~~each~~stock ~~period~~associated ~~end~~with ~~based~~the onconvertible ~~enacted~~debt ~~tax~~using ~~laws~~the ~~and~~if-converted ~~statutory~~method. ~~tax~~Potential ~~rates~~common ~~applicable~~shares tothat ~~the~~have ~~periods~~an anti-dilutive ineffect ~~which~~(i.e., ~~the~~those ~~differences~~that ~~are~~increase ~~expected~~earnings toper ~~affect~~share ~~taxable~~or ~~income.~~decrease ~~Valuation~~loss ~~allowances~~per share) are ~~established,~~excluded ~~when~~from ~~necessary,~~the tocalculation ~~reduce~~of ~~deferred~~diluted EPS. As ~~tax~~of ~~assets~~June to30, 2024 and 2023, the ~~amount~~Company ~~expected~~was not party to beany ~~realized~~contract to issue shares.

~~ASC 740-10-30 requires income tax positions to meet a more-likely-than-not recognition threshold to be recognized in the financial statements~~O. ~~Under~~ ~~ASC 740-10-30, tax positions that previously failed to meet the more-likely-than-not threshold should be recognized in the first~~Recently ~~subsequent~~adopted ~~financial~~accounting ~~reporting period in which that threshold is met.~~pronouncements

~~The application~~We ofdo ~~tax~~not believe ~~laws~~that ~~and~~any ~~regulations~~recently isissued ~~subject~~but tonot ~~legal~~yet ~~and~~effective ~~factual~~accounting ~~interpretation~~standards, ~~judgment~~if ~~and~~currently ~~uncertainty.~~adopted, ~~Tax~~would ~~laws~~have ~~and regulations themselves are subject to change as~~ a ~~result~~material ofeffect ~~changes~~on inthe Company’s ~~fiscal~~consolidated ~~policy,~~financial ~~changes in legislation~~position, ~~the~~statements ~~evolution~~ of ~~regulations~~operations and ~~court rulings.~~cash Therefore, the actual liability may be materially different from our estimates, which could result in the need to record additional tax liabilities or potentially reverse previously recorded tax liabilities or the deferred tax asset valuation allowanceflows.

~~As a result of the implementation of ASC 740~~F-10, the Company made a comprehensive review of its portfolio of tax positions in accordance with recognition standards established by ASC 740-10. The Company recognized no material adjustments to liabilities or shareholder’s equity as a result of the implementation.

~~O. Earnings~~LONGDUODUO ~~(loss)~~COMPANY ~~per~~LIMITED ~~share~~AND SUBSIDIARIES

~~The Company~~NOTES ~~computes~~TO ~~earnings~~CONSOLIDATED ~~(loss)~~FINANCIAL per share (“EPS”) in accordance with ASC 260, Earnings Per Share. ASC 260 requires companies with complex capital structures to present basic and diluted EPS. Basic EPS is measured as net income (loss) divided by the weighted average common shares outstanding during the period.STATEMENTS

~~Diluted EPS~~FOR isTHE ~~similar~~THREE toMONTHS ~~basic~~ENDED ~~EPS~~SEPTEMBER ~~but presents the dilutive effect on a per share basis of contracts to issue common shares (e.g.~~30, ~~convertible~~2024 ~~securities,~~AND ~~options~~SEPTEMBER and warrants) as if they had been converted at the beginning of the periods presented, or issuance date, if later. The computation of diluted EPS includes the estimated impact of the exercise of contracts to purchase common stock using the treasury stock method and the potential shares of converted common stock associated with the convertible debt using the if-converted method. Potential common shares that have an anti-dilutive effect (i.e., those that increase earnings per share or decrease loss per share) are excluded from the calculation of diluted EPS. As of March 31, 2024 and June 30, 2023~~, the Company was not party to any contract to issue shares.~~

~~P. Recently adopted accounting pronouncements~~(UNAUDITED)

~~We do~~NOTE not believe that any recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s consolidated financial position, statements of operations and cash flows3. PREPAYMENTS

~~NOTE~~Prepayments 3represent payments in advance to suppliers for expenses, equipment, leasing and products. ~~PREPAYMENTS~~As of September 30, 2024 and June 30, 2024 prepayments were $162,593 and $124,427, respectively.

~~Prepayments~~NOTE ~~represent payments in advance to suppliers for expenses, equipment, leasing and products~~4. AsPROPERTY ofAND ~~March 31, 2024 and June 30, 2023 prepayments were $225,725 and $68,341, respectively.~~EQUIPMENT

OnAt ~~February 8~~September 30, 2024, ~~the~~and ~~Company~~June ~~executed an engagement letter with Network 1 Financial Services~~30, ~~Inc (“Network 1”). The letter provides for Network 1 to act as an underwriter of a proposed offering of ordinary shares of the Company. The Company delivered $100,000 cash to Network 1 in February~~ 2024 ~~as an advance to be applied towards an Accountable Expense Allowance of up to $225~~,~~000~~ toproperty beand ~~paid to Network 1. The $100~~equipment,~~000~~ ~~advance is included in “Prepayments” in the Consolidated Balance Sheet~~ at ~~March 31~~cost, ~~2024.~~consisted of:

F-10

	September 30,		June 30,
	2024		2024

Office equipment and furniture	$	505,824	$	461,562
Leasehold improvements		71,932		40,506
Total		577,756		502,068
Accumulated depreciation		185,347		148,582
Total property and equipment, net	$	392,409	$	353,486

~~LONGDUODUO~~The Company ~~COMPANY~~recorded ~~LIMITED~~depreciation ~~AND~~expense ~~SUBSIDIARIES~~of $29,998 for the three months ended September 30, 2024, of which $27,624 was recorded as operating expense and $2,374 was recorded as cost of revenue.

~~NOTES~~The Company TOrecorded ~~CONSOLIDATED~~depreciation ~~FINANCIAL~~expense ~~STATEMENTS~~of $15,516 for the three months ended September 30, 2023, of which $14,016 was recorded as operating expense and $1,500 was recorded as cost of revenue.

~~FOR~~NOTE ~~THE~~5. ~~THREE~~RELATED ~~AND~~PARTY ~~NINE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023~~TRANSACTIONS

~~(UNAUDITED)~~Due to related parties

~~NOTE 4.~~Due ~~PROPERTY~~to ~~AND~~related ~~EQUIPMENT~~parties consists of the following:

At March 31, 2024 and June 30, 2023, property and equipment, at cost, consisted of:

Name of related party	September 30, 2024		June 30, 2024
Zhang Liang	$	2,299	$	2,233
Total	$	2,299	$	2,233

	March 31,			June 30,
	2024			2023
Office equipment and furniture	$	432,484		$	204,645
Leasehold improvements		15,867			72,026
Total		448,351			276,671
Accumulated depreciation		(122,913	)		(123,952	)
Total property and equipment, net	$	325,438		$	152,719

Until November 29, 2023, Zhang Liang was the President and Chairman of the Board of Longduoduo. Mr. Zhang Liang controls approximately 51% of Longduoduo’s issued and outstanding common stock. These advances due to related parties are unsecured, repayable on demand, and bear no interest.

~~The~~NOTE ~~Company recorded depreciation expense of $37,234 for the three months ended March 31, 2024, of which $32,835 was recorded as operating expense and $4,399 was recorded as cost of revenue~~6. ~~The~~INCOME ~~Company recorded depreciation expense of $75,937 for the nine months ended March 31, 2024, of which $68,106 was recorded as operating expense and $7,831 was recorded as cost of revenue.~~TAXES

~~The~~United Company recorded depreciation expense of $16,898 for the three months ended March 31, 2023, of which $14,743 was recorded as operating expense and $2,155 was recorded as cost of revenue. The Company recorded depreciation expense of $51,071 for the nine months ended March 31, 2023, of which $45,362 was recorded as operating expense and $5,709 was recorded as cost of revenue.States

~~NOTE~~Longduoduo 5is subject to the U.S. ~~RELATED~~corporation ~~PARTY~~tax ~~TRANSACTIONS~~rate of 21%.

~~Due~~Hong ~~to related parties~~Kong

~~Due~~Longduoduo HK was incorporated in Hong Kong and is subject to ~~related~~Hong ~~parties~~Kong ~~consists~~profits oftax. Longduoduo HK is subject to Hong Kong taxation on its activities conducted in Hong Kong and income arising in or derived from Hong Kong. The applicable statutory tax rate is 16.5%. The Company did not have any income (loss) subject to the ~~following:~~Hong Kong profits tax.

Name of related party	March 31, 2024		June 30, 2023
Zhang Liang	$	2,245	$	69,419
Zhou Hongxiao		-		35,192
Total	$	2,245	$	104,611

F-11

~~Until November~~LONGDUODUO ~~29,~~COMPANY ~~2023,~~LIMITED ~~Zhang~~AND Liang was the President and Chairman of the Board of Longduoduo. Mr. Zhang Liang controls approximately 51% of Longduoduo’s issued and outstanding common stock. Zhou Hongxiao is the CEO and a director of Longduoduo. These advances due to related parties are unsecured, repayable on demand, and bear no interest.SUBSIDIARIES

~~NOTE 6.~~NOTES ~~INCOME~~TO ~~TAXES~~CONSOLIDATED FINANCIAL STATEMENTS

~~United~~FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2024 ~~States~~AND SEPTEMBER 30, 2023

~~Longduoduo is subject to the U.S. corporation tax rate of 21%.~~(UNAUDITED)

~~Hong Kong~~China

Longduoduo ~~HK was~~Health ~~incorporated~~Technology ~~in Hong Kong~~ and issubsidiaries ~~subject~~are ~~to Hong Kong profits tax. Longduoduo HK is~~ subject to ~~Hong~~a 25% ~~Kong~~standard ~~taxation~~enterprise ~~on its activities conducted in Hong Kong and~~ income ~~arising~~tax in orthe ~~derived from Hong Kong~~PRC. The ~~applicable~~Company ~~statutory~~accrued ~~tax~~$180 ~~rate~~and ~~is 16.5%.~~$140,900 ~~The~~of ~~Company~~PRC ~~did~~income ~~not~~tax ~~have~~for ~~any~~the ~~income~~three ~~(loss)~~months ~~subject~~ended toSeptember ~~the~~30, ~~Hong~~2024 ~~Kong~~and ~~profits tax~~2023.

~~China~~A summary of income (loss) before income taxes for domestic and foreign locations for the three months ended September 30, 2024 and 2023 is as follows:

Longduoduo Health Technology and subsidiaries are subject to a 25% standard enterprise income tax in the PRC. The Company accrued $408,265 of PRC income tax for the nine months ended March 31, 2024. There was no provision for income taxes for the nine months ended March 31, 2023.

	For the Three Months Ended September 30,
	2024			2023
United States	$	(109,772	)	$	(33,376	)
Foreign		50,448			469,020
Total Income (loss) before income taxes	$	(59,324	)	$	435,644

~~F-11~~The difference between the U.S. federal statutory income tax rate and the Company’s effective tax rate was as follows:

LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES

	For the Three Months Ended September 30,
	2024			2023
Income tax (benefit) at USA statutory rate		(21	)%		(21	)%
U.S. valuation allowance		21	%		21	%
Income tax (benefit) at USA effective rate		(0	)%		(0	)%

~~NOTES~~The TOdifference ~~CONSOLIDATED~~between ~~FINANCIAL~~the ~~STATEMENTS~~PRC statutory income tax rate and the PRC effective tax rate was as follows:

FOR THE THREE AND NINE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023

	For the Three Months Ended September 30,
	2024			2023
Income tax (benefit) at PRC statutory rate		25	%		25	%
Utilization of net operating loss carry forward		0	%		(1	)%
PRC valuation allowance		(25	)%		8	%
Other		0	%		(2	)%
Income tax (benefit) at PRC effective rate		0	%		30	%

~~(UNAUDITED)~~The Company did not recognize deferred tax assets since it is not more likely than not that it will realize such deferred taxes. The deferred tax would apply to Longduoduo in the U.S. and Longduoduo Health Technology and subsidiaries in China.

~~A summary~~As of ~~income~~September 30, (2024, Longduoduo Health Technology and its subsidiaries have total net operating loss) ~~before~~carry ~~income~~forwards ~~taxes~~of ~~for~~approximately ~~domestic~~$464,251 in the PRC that expire through 2029. Due to the uncertainty of utilizing these carry forwards, the Company provided a 100% allowance on all deferred tax assets of approximately $13,926 and ~~foreign~~$9,696 related ~~locations~~to ~~for~~its operations in the ~~three~~PRC as of September 30, 2024 and ~~nine~~June 30, 2024, respectively. The PRC valuation allowance has increased by $4,230 and decreased by $36,589 for the three months ended ~~March~~September 3130, 2024 and 2023, ~~is as follows:~~respectively.

	For the Three Months Ended March 31,
	2024			2023
United States	$	(48,021	)	$	(32,008	)
Foreign		757,282			(439,300	)
Income (loss) before income taxes	$	709,261		$	(471,308	)

The Company incurred losses from its United States operations during the three months ended September 30, 2024 of approximately $109,772. The Company’s United States operations consist solely of ownership of its foreign subsidiaries, and the losses arise from administration expenses. Accordingly, management provided a 100% valuation allowance of approximately $236,488 and $213,436 against the deferred tax assets related to the Company’s United States operations as of September 30, 2024 and June 30, 2024, respectively, because the deferred tax benefits of the net operating loss carry forwards in the United States are not likely to be utilized. The US valuation allowance has increased by approximately $23,052 and $7,009 for the three months ended September 30, 2024, and 2023, respectively.

	For the Nine Months Ended March 31,
	2024			2023
United States	$	(183,687	)	$	(124,397	)
Foreign		1,587,493			(838,503	)
Income (loss) before income taxes	$	1,403,806		$	(962,900	)

F-12

~~The difference~~LONGDUODUO ~~between~~COMPANY ~~the~~LIMITED ~~U.S.~~AND ~~federal statutory income tax rate and the Company’s effective tax rate was as follows:~~SUBSIDIARIES

	For the Nine Months Ended March 31,
	2024			2023
Income tax (benefit) at USA statutory rate		(21	)%		(21	)%
U.S. valuation allowance		21	%		21	%
Income tax (benefit) at USA effective rate		(0	)%		(0	)%

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~The difference~~FOR ~~between~~THE ~~the~~THREE ~~PRC~~MONTHS ~~statutory~~ENDED ~~income~~SEPTEMBER ~~tax~~30, ~~rate~~2024 AND ~~and~~SEPTEMBER ~~the~~30, ~~PRC effective tax rate was as follows:~~2023

	For the Nine Months Ended March 31,
	2024			2023
Income tax (benefit) at PRC statutory rate		25	%		(25	)%
Utilization of net operating loss carry forward		(1	)%		-
PRC valuation allowance		2	%		25	%
Other		-			-
Income tax (benefit) at PRC effective rate		26	%		(0	)%

(UNAUDITED)

~~For~~The Company ~~the~~is ~~nine~~subject ~~months~~to ~~ended~~examination ~~March~~by ~~31, 2023,~~ the ~~Company~~Internal ~~did~~Revenue ~~not~~Service ~~recognize~~(IRS) ~~deferred~~in ~~tax~~the ~~assets~~United ~~since~~States atas ~~that~~well ~~time~~as itby ~~did~~the ~~not~~taxing ~~appear~~authorities ~~more~~in ~~likely~~China, where ~~than~~the Company has ~~not~~significant ~~that~~business ~~it would realize such deferred taxes~~operations. The ~~deferred~~table ~~tax~~below ~~would~~presents ~~apply~~the toearliest ~~Longduoduo~~tax inyear ~~the~~that ~~U.S.~~remains ~~and~~subject ~~Longduoduo~~to ~~Health Technology~~examination ~~and~~by ~~subsidiaries~~major ~~in China~~jurisdiction.

As of March 31, 2024, Longduoduo Health Technology and its subsidiaries have total net operating loss carry forwards of approximately $504,699 in the PRC that expire through 2028. Due to the uncertainty of utilizing these carry forwards, the Company provided a 100% allowance on all deferred tax assets of approximately $126,175 and $87,494 related to its operations in the PRC as of March 31, 2024 and June 30, 2023, respectively. The PRC valuation allowance increased by $38,681 and $209,904 for the nine months ended March 31, 2024 and March 31, 2023, respectively.

		Earliest tax year that remains subject to examination
U.S. Federal		June 30, 2021
China		June 30, 2020

~~The~~NOTE ~~Company incurred losses from its United States operations during the nine months ended March 31, 2024 of approximately $183,687~~7. The Company’s United States operations consist solely of ownership of its foreign subsidiaries, and the losses arise from administration expenses. Accordingly, management provided a 100% valuation allowance of approximately $209,902 and $171,327 against the deferred tax assets related to the Company’s United States operations as of March 31, 2024 and June 30, 2023, respectively, because the deferred tax benefits of the net operating loss carry forwards in the United States are not more likely than not to be utilized. The US valuation allowance increased by approximately $38,574 and $26,123 for the nine months ended March 31, 2024, and March 31, 2023, respectively.LEASES

~~F-12~~On June 1, 2024, Chengheng leased an office space (approximately 451 square meters) under an operating lease agreement from Ding Jun. Under the terms of the agreement, Chengheng is committed to make lease payments of approximately $2,774 (RMB20,000) for the period between June 1, 2024 and May 31, 2025.

~~LONGDUODUO~~On March 10 of 2024, Longduoduo Health Technology leased office space ~~COMPANY~~(approximately 150 square ~~LIMITED~~meters) ~~AND~~under ~~SUBSIDIARIES~~an operating lease agreement with Liu Libao. Under the terms of the agreement, Longduoduo Health Technology is committed to make lease payments of approximately $4,160 (RMB30,000) for the period between March 10, 2024 and March 10, 2025.

~~NOTES~~On April 1 of 2024, Tianju leased office space TO(approximately 595 square ~~CONSOLIDATED~~meters) ~~FINANCIAL~~under ~~STATEMENTS~~an operating lease agreement with Han Ruijun. Under the terms of the agreement, Tianju is committed to make lease payments of approximately $19,000 (RMB137,000) annually for the period between April 1, 2024 and March 31, 2027.

~~FOR~~On August 14, 2024, Qingguo leased office space ~~THE~~(approximately 482 square ~~THREE~~meters) ~~AND~~under ~~NINE~~an ~~MONTHS~~operating ~~ENDED~~lease ~~MARCH~~agreement 31with Inner Mongolia Chuangfuhui Enterprise Management Co., Ltd. Under the terms of the agreement, Qingguo is committed to make lease payments of approximately $30,510 (RMB 220,000) for the period between September 10, 2024 ~~AND~~and ~~MARCH~~September 3110, ~~2023~~2025.

~~(UNAUDITED)~~Leases with an initial term of 12 months or less are not recorded on the balance sheet. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company did not combine lease and non-lease components.

~~The~~Most leases ~~Company~~do isnot ~~subject~~include options to ~~examination~~renew. byThe ~~the~~exercise ~~Internal~~of ~~Revenue~~lease ~~Service~~renewal ~~(IRS)~~options inhas to be agreed to by the ~~United~~lessors. ~~States~~The asdepreciable ~~well~~life asof assets and leasehold improvements are limited by the ~~taxing~~term ~~authorities~~of ~~in China~~leases, ~~where~~unless ~~the Company has~~there ~~significant~~is ~~business~~a ~~operations~~transfer of title or purchase option reasonably certain of exercise. ~~The~~ ~~table~~Lease ~~below~~expense ~~presents~~is recognized on a straight-line basis over the ~~earliest~~term ~~tax~~of ~~year~~the ~~that~~lease. ~~remains subject~~Lease expense related to ~~examination~~noncancelable byoperating leases ~~major~~was ~~jurisdiction.~~$13,394 and $7,140 for the three months ended September 30, 2024 and 2023, respectively.

		Earliest tax year that remains subject to examination
U.S. Federal		June 30, 2021
China		June 30, 2020

Balance sheet information related to the Company’s leases is presented below:

NOTE 7. LEASES

	September 30, 2024		June 30, 2024
Assets
Operating lease right of use assets	$	47,354	$	50,070
Liabilities
Operating lease liabilities – current	$	18,431	$	17,618
Operating lease liabilities – non-current		19,159		18,314
Total Operating lease liabilities	$	37,590	$	35,932

In April 2021, Qingguo entered into an operating cooperation agreement with Hohhot Aihua Traditional Chinese Medicine Hospital. Under the terms Qingguo was able to use office space (approximately 700 square meters) free of charge during the period between April 1, 2021 to March 31, 2026. On May 27, 2022, the agreement was amended to provide for the lease of this office space under a nonF-cancellable operating lease agreement. Under terms of the lease agreement, from May 27, 2022, Qingguo was committed to make lease payments of approximately $9,295 per year for 1 year. On August 31, 2023, the lease agreement was terminated.13

~~On July~~LONGDUODUO 2,COMPANY ~~2022~~LIMITED ~~the~~AND Company leased a staff dormitory under a non-cancellable operating lease agreement with a third party, Xi Ling. Under the terms of the agreement, the Company was committed to make total lease payments of $20,561, or RMB 150,000, with lease payments of $6,854 per year for the lease period from July 2, 2022 to July 2, 2025. On June 30, 2023, the agreement was terminated.SUBSIDIARIES

~~On April~~NOTES 4,TO ~~2023,~~CONSOLIDATED ~~Chengheng~~FINANCIAL leased office space (approximately 957 square meters) under an operating lease agreement with Jinrong Holding (Hainan) Group Co., LTD. Inner Mongolia branch. Under the terms of the agreement as supplemented October 3, 2023, Chengheng was committed to make lease payments of approximately $7,062, or RMB 50,000, from January 1, 2024 to March 31, 2024. On April 1, 2024, Chengheng entered into a lease agreement with Ding Jun. Under the terms of the new lease, Chengheng is able to use office space (approximately 451 square meters) free of charge during the period from April 1, 2024 to May 31, 2024. After lessor completes the decoration of the office space, the parties are to sign a new lease agreement.STATEMENTS

~~On August~~FOR ~~31,~~THE ~~2023,~~THREE ~~Qingguo~~MONTHS ~~leased~~ENDED ~~office~~SEPTEMBER ~~space (approximately 482 square meters) under an operating lease agreement with Inner Mongolia Chuangfuhui Enterprise Management Co.~~30, ~~Ltd. Under the terms of the agreement, Qingguo is committed to make lease payments of~~2024 ~~approximately~~AND $SEPTEMBER 30,~~157 (RMB 220,000)~~ ~~for the period between September 10,~~ 2023 ~~and September 10, 2024.~~

Leases with an initial term of 12 months or less are not recorded on the balance sheet. Operating lease cost is recognized as a single lease cost on a straight-line basis over the lease term and is recorded in selling, general and administrative expenses. For lease agreements entered into or reassessed after the adoption of Topic 842, the Company did not combine lease and non-lease components.(UNAUDITED)

~~Most leases~~As domost ~~not include options to renew. The exercise~~ of ~~lease renewal options has to be agreed to by~~ the ~~lessors.~~Company’s ~~The~~leases ~~depreciable~~do ~~life~~not provide ofan ~~assets~~implicit ~~and~~rate, ~~leasehold improvements are limited by~~ the ~~term~~Company ofuses 1-5 years ~~the~~borrowing ~~respective~~rate ~~leases,~~from ~~unless~~bank ~~there is a transfer~~ of 3.95% ~~title~~and ~~or a purchase option reasonably certain of exercise~~4.75% ~~Lease~~based ~~expense is recognized~~ on ~~a straight-line basis over~~ the ~~term~~information ~~of the lease. Lease expense~~available ~~related~~at tocommencement ~~noncancelable~~date ~~operating~~in ~~leases~~determining ~~was $0 and $57,687 for~~ the ~~nine~~present ~~months~~value ~~ended~~of ~~March~~lease ~~31, 2024 and 2023, respectively~~payments.

~~Balance sheet~~Maturities ~~information~~of ~~related~~lease toliabilities ~~the~~are ~~Company’s~~as ~~leases is presented below~~follows:

	March 31, 2024			June 30, 2023
For the year ending September 30:
Assets
2025	$	19,530
Operating lease right of use assets	$	-		$	13,470
2026		19,530
Liabilities
Total lease payments		39,060
Operating lease liabilities – current	$	-		$	6,579
Less: imputed interest		(1,470	)
Operating lease liabilities – non-current		-			6,891
Total lease liabilities	$	37,590
Total Operating lease liabilities	$	-		$	13,470

~~F-13~~NOTE 8. CONTINGENCIES

~~LONGDUODUO COMPANY LIMITED AND SUBSIDIARIES~~Contingencies

~~NOTES~~Certain TOconditions ~~CONSOLIDATED~~may ~~FINANCIAL~~exist ~~STATEMENTS~~as of the date the consolidated financial statements are issued which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company’s management and legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought.

~~FOR~~If the assessment ~~THE~~of ~~THREE~~a ~~AND~~contingency ~~NINE~~indicates ~~MONTHS~~that ~~ENDED~~it ~~MARCH~~is 31probable that a material loss has been incurred and the amount of the liability can be estimated, then ~~2024~~the ~~AND~~estimated ~~MARCH~~liability 31would be accrued in the Company’s financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, ~~2023~~or is probable but cannot be estimated, then the nature of the contingent liability, together with an estimate of the range of possible loss if determinable and material would be disclosed.

~~(UNAUDITED)~~Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.

~~NOTE~~The Company 8.was ~~CONTINGENCIES~~not subject to any material loss contingency as of September 30, 2024 and June 30, 2024.

~~Contingencies~~NOTE 9. STOCKHOLDERS’ EQUITY

~~Certain conditions~~On ~~may~~February ~~exist~~20, as2023, of the ~~date~~Company ~~the consolidated financial statements are~~ issued ~~which may result in a loss to the Company but which~~5,000 ~~will~~common ~~only~~shares be(valued ~~resolved~~at ~~when~~$384,500) ~~one or more future events occur or fail~~ to ~~occur.~~Kang ~~The~~Liping ~~Company’s~~(Chief ~~management~~Financial ~~and~~Officer ~~legal counsel assess such contingent liabilities, and such assessment inherently involves an exercise~~ of ~~judgment. In assessing loss contingencies related to legal proceedings that are pending against~~ the Company) ~~or unasserted claims that may result in such proceedings, the Company’s legal counsel evaluates the perceived merits of any legal proceedings or unasserted claims~~ as ~~well as the perceived merits of the amount of relief sought or expected to be sought~~compensation.

IfOn September 21, 2023, the Company filed with the ~~assessment~~Nevada Secretary of State a ~~contingency~~Certificate ~~indicates~~of ~~that~~Change itPursuant isto ~~probable~~NRS ~~that~~78.209. aThe ~~material~~Certificate ~~loss~~of ~~has~~Change ~~been~~provided ~~incurred~~for ~~and~~a ~~the~~1-for-10 ~~amount~~reverse split of the ~~liability can~~Registrant’s beoutstanding ~~estimated,~~common ~~then~~stock ~~the~~effective ~~estimated~~at ~~liability~~the ~~would~~close beof ~~accrued~~business inon ~~the~~September ~~Company’s~~26, ~~financial statements~~2023. IfThe ~~the~~Certificate ~~assessment indicates~~of ~~that~~Change adid ~~potential~~not ~~material~~change ~~loss~~the ~~contingency~~number isof ~~not~~authorized ~~probable~~shares ~~but~~of isCommon ~~reasonably possible~~Stock, orwhich isremains ~~probable~~500,000,000 ~~but~~shares. ~~cannot~~No befractional ~~estimated,~~shares ~~then~~were ~~the~~issued ~~nature~~in ofconnection with the ~~contingent~~reverse ~~liability,~~stock ~~together~~split; ~~with~~any anfractional ~~estimate~~shares ofthat resulted from the ~~range~~reverse ofsplit ~~possible~~were ~~loss~~rounded ifup ~~determinable~~to ~~and~~the ~~material~~nearest whole ~~would~~share. beThe ~~disclosed~~accompanying financial statements have been adjusted to retroactively reflect this reverse stock split.

~~Loss contingencies considered to be remote by management are generally not disclosed unless they involve guarantees, in which case the guarantee would be disclosed.~~F-14

~~The Company~~LONGDUODUO ~~was~~COMPANY ~~not~~LIMITED ~~subject~~AND ~~to any material loss contingency as of March 31, 2024 and June 30, 2023.~~SUBSIDIARIES

~~NOTE 9.~~NOTES ~~STOCKHOLDERS’~~TO ~~EQUITY~~CONSOLIDATED ~~(DEFICIT)~~FINANCIAL STATEMENTS

~~On February~~FOR ~~20,~~THE ~~2023,~~THREE ~~the~~MONTHS ~~Company~~ENDED ~~issued 5,000 common~~SEPTEMBER ~~shares (valued at $384~~30,~~500)~~ ~~to Kang Liping (Chief Financial Officer of the~~2024 ~~Company)~~AND asSEPTEMBER ~~compensation.~~30, 2023

On September 21, 2023, the Company filed with the Nevada Secretary of State a Certificate of Change Pursuant to NRS 78.209. The Certificate of Change provided for a 1-for-10 reverse split of the Registrant’s outstanding common stock effective at the close of business on September 26, 2023. The Certificate of Change did not change the number of authorized shares of Common Stock, which remains 500,000,000 shares. No fractional shares were issued in connection with the reverse stock split; any fractional shares that resulted from the reverse split were rounded up to the nearest whole share. The accompanying financial statements have been adjusted to retroactively reflect this reverse stock split.(UNAUDITED)

NOTE 10. BASIC AND DILUTED EARNINGS PER SHARE

Basic ~~net~~ net income (loss) per share is computed using the weighted average number of common shares outstanding during the period. Diluted net ~~income~~ income (loss) per share is computed using the weighted average number of common shares and, if dilutive, potential common shares outstanding during the period. Potential common shares comprise shares issuable upon the exercise of share-based awards, using the treasury stock method. The reconciliation of the numerators and denominators of the basic and diluted earnings per share computations is shown as as follows:

	For the Three Months Ended March 31,
	For the Three Months Ended September 30,
	2024			2023
Numerator:
Net Income (loss) attributable to common stockholders	$	511,544		$	(430,807	)
Net income (loss) attributable to common stockholders	$	(57,303	)	$	284,217
Denominator:
Basic and diluted weighted-average number of shares outstanding		30,005,016			30,~~000~~005,008
Net income (loss) per share:
Basic and diluted	$	(0.~~017~~002	)	$	(0.~~014~~01	)

FNOTE 11. NON-14CONTROLLING INTERESTS

~~LONGDUODUO~~Qingguo, ~~COMPANY~~Chengheng, ~~LIMITED~~Rongbin ~~AND~~and ~~SUBSIDIARIES~~Tianju are the Company’s majority-owned subsidiaries which are consolidated in the Company’s financial statements with non-controlling interests recognized. The Company holds 90%, 80%, 80% and 51% interest of Qingguo, Chengheng, Rongbin and Tianju as of September 30, 2024, respectively.

~~NOTES~~As of September TO30, ~~CONSOLIDATED~~2024 ~~FINANCIAL~~and ~~STATEMENTS~~June 30, 2024, the non-controlling interests in the consolidated balance sheet was $78,910 and 78,336, respectively.

~~FOR~~For ~~THE~~the ~~THREE~~three ~~AND~~months ~~NINE~~ended ~~MONTHS~~September ~~ENDED MARCH 31~~30, 2024, ~~AND~~the ~~MARCH~~comprehensive 31income attributable to common stockholders and non-controlling interests were $(13,089) and ~~2023~~$574, respectively.

~~(UNAUDITED)~~For the three months ended September 30, 2023, the comprehensive income attributable to common stockholders and non-controlling interests were $282,998 and $10,598, respectively.

	For the Nine Months Ended March 31,
	2024		2023
Numerator:
Net income (loss) attributable to common stockholders	$	944,450	$	(868,378	)
Denominator:
Basic and diluted weighted-average number of shares outstanding		30,005,016		30,000,008
Net income (loss) per share:
Basic and diluted	$	0.031	$	(0.029	)

NOTE 12. SUBSEQUENT EVENTS

~~NOTE~~Management 11has evaluated subsequent events through the date which the consolidated financial statements were available to be issued. ~~NON-CONTROLLING~~There ~~INTERESTS~~are no subsequent events that require disclosure in accordance with FASB ASC Topic 855, “Subsequent Events.”

~~Qingguo, Chengheng, Rongbin and Tianju are the Company’s majority~~F-owned subsidiaries which are consolidated in the Company’s financial statements with non-controlling interests recognized. The Company holds 90%, 80%, 80% and 51% interest of Qingguo, Chengheng, Rongbin and Tianju as of March 31, 2024, respectively.15

~~As of~~Item ~~March~~2. ~~31,~~Management’s ~~2024~~Discussion and ~~June~~Analysis ~~30,~~of ~~2023,~~Financial ~~the~~Condition ~~non-controlling~~and ~~interests~~Results inof ~~the consolidated balance sheet was $22,109 and ($28,698), respectively.~~Operations

~~For~~The following discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements and the ~~three~~notes ~~months~~thereto ~~ended~~included ~~March~~elsewhere in ~~31,~~this ~~2024~~Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the ~~comprehensive~~United States. ~~income~~The ~~attributable~~preparation of such financial statements requires us to ~~common~~make ~~stockholders~~estimates and ~~non-controlling~~judgments ~~interests~~that ~~were~~affect the reported amounts of assets, ~~$501~~liabilities,~~507~~ revenues, and $6expenses. On an ongoing basis,~~344~~ we evaluate these estimates, ~~respectively.~~including ~~For~~those ~~the~~related ~~nine~~to ~~months~~useful ~~ended~~lives ~~March~~of 31real estate assets, ~~2024~~bad debts, ~~the~~impairment, ~~comprehensive~~contingencies ~~income~~and ~~attributable~~litigation. toWe ~~common~~base ~~stockholders~~ our estimates on historical experience and ~~non-controlling~~on ~~interests~~various ~~were~~other assumptions ~~$939~~that are believed to be reasonable under the circumstances,~~973~~ the results of which form the basis for making judgments about the carrying values of assets and ~~$50,807,~~liabilities ~~respectively~~that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

~~For the~~Application ~~three~~of ~~months~~Critical ~~ended~~Accounting March 31, 2023, the comprehensive loss attributable to common stockholders and non-controlling interests were $437,521 and $41,181, respectively. For the nine months ended March 31, 2023, the comprehensive loss attributable to common stockholders and non-controlling interests were $854,828 and $93,109, respectively.Policies

~~NOTE~~The discussion and analysis of the Company’s 12financial condition and results of operations is based upon its condensed consolidated financial statements, which have been prepared in accordance with United States generally accepted accounting principles. ~~SUBSEQUENT~~The ~~EVENTS~~preparation of these financial statements requires us to make significant estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate.

~~Management has~~In ~~evaluated~~connection ~~subsequent~~with ~~events~~the ~~through~~preparation ~~the~~of ~~date~~our onfinancial statements ~~which~~for the ~~consolidated~~three ~~financial~~months ~~statements~~ended ~~were~~September ~~available~~30, to2024, bethere ~~issued.~~was ~~There are~~ no ~~subsequent~~accounting ~~events~~estimate ~~that~~made ~~require~~which ~~disclosure~~was in(a) ~~accordance~~subject ~~with~~to ~~FASB~~a ~~ASC~~high ~~Topic~~degree of ~~855,~~uncertainty ~~“Subsequent~~and ~~Events~~(b) material to our results.”

~~F-15~~Results of Operations

~~Item 2.~~The ~~Management’s~~following ~~Discussion~~table ~~and~~shows ~~Analysis~~key components of ~~Financial~~the unaudited ~~Condition~~results ~~and~~of ~~Results~~operations ofduring ~~Operations~~the three months ended September 30, 2024 and 2023:

The following discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements and the notes thereto included elsewhere in this Quarterly Report on Form 10-Q, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of such financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses. On an ongoing basis, we evaluate these estimates, including those related to useful lives of real estate assets, bad debts, impairment, contingencies and litigation. We base our estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There can be no assurance that actual results will not differ from those estimates.

	For the Three Months Ended
	September 30,
	2024			2023		Change
	(Unaudited)			(Unaudited)		$			%
Total revenue	$	769,072		$	1,587,433	$	(818,361	)		(52	)%
Cost of revenue		32,276			62,351		(30,075	)		(48	)%
Gross Profit		736,796			1,525,082		(788,286	)		(52	)%
Total operating expenses		798,872			1,090,800		(291,928	)		(27	)%
Income (loss) from operations		(62,076	)		434,282		(496,358	)		(114	)%
Other income, net		2,752			1,362		1,390			102	%
Income (Loss) before income taxes		(59,324	)		435,644		(494,698	)		(114	)%
Income tax		180			140,900		(140,720	)		(100	)%
Net Income (Loss)	$	(59,504	)	$	294,744	$	(354,248	)		(120	)%

~~Application of Critical Accounting Policies~~2

~~The discussion~~During ~~and analysis of~~ the ~~Company’s~~three ~~financial~~months ended ~~condition~~September ~~and~~30, ~~results~~2024, ofour ~~operations~~total isrevenue ~~based~~was ~~upon~~$769,072, ~~its~~of ~~condensed~~which ~~consolidated financial statements~~$46,595 ~~which~~was ~~have~~attributable ~~been~~to ~~prepared~~the insale ~~accordance~~of ~~with~~healthcare ~~United~~services, ~~States~~primarily derived ~~generally~~from ~~accepted~~sales ~~accounting principles. The preparation~~ of ~~these~~“Immunological ~~financial~~Ozonated ~~statements~~Autohemotherapy”, ~~requires~~“Meridian-regulating usand toConsciousness-restoring ~~make~~Iatrotechnics”, “Assay”, ~~significant~~“PRP” ~~estimates~~ and ~~judgments~~other ~~that~~healthcare ~~affect~~services. ~~the~~The ~~reported~~remaining ~~amounts~~$722,477 of ~~assets,~~revenue ~~liabilities,~~was attributable to commissions ~~revenues~~earned ~~and~~by ~~expenses,~~the ~~and~~Company ~~related~~from ~~disclosure~~its ofservice ~~contingent~~as ~~assets~~sales ~~and~~agent ~~liabilities~~for Honghai. ~~These~~In ~~items~~June ~~are~~of ~~monitored~~2023, ~~and~~the ~~analyzed~~Company bybegan ~~management for~~to ~~changes~~engage in ~~facts~~the ~~and~~sales ~~circumstances,~~agent business and ~~material~~focused ~~changes~~on inthe ~~these~~sales ~~estimates~~of ~~could~~preventive ~~occur~~healthcare insolutions ~~the~~administered ~~future.~~by ~~Changes~~Honghai, inwith ~~estimates~~whom ~~are~~we ~~recorded in~~have ~~the~~a ~~period~~Sales inAgency ~~which they become known~~Agreement. ~~The~~As ~~Company~~of September ~~bases~~30, ~~its~~2024, ~~estimates~~we onoperate ~~historical~~through ~~experience~~five ~~and~~entities: ~~various~~Longduoduo ~~other~~Health ~~assumptions~~Technology, ~~that we~~Tianju, ~~believe~~Qingguo, toRongbin beand ~~reasonable~~Chengheng, ~~under~~which ~~the~~are established ~~circumstances.~~in ~~Actual~~Ordos, ~~results~~Ulanqab, ~~may~~Huhhot, ~~differ~~Baotou ~~from~~and ~~our~~Ordos, ~~estimates~~respectively, ifwhich ~~past~~include ~~experience~~four orof ~~other~~the ~~assumptions do~~largest ~~not~~cities ~~turn~~in ~~out~~Inner toMongolia, ~~be substantially accurate~~China.

InQuarter to quarter revenue ~~connection~~fell by 52% as compared with the ~~preparation~~operating revenue of ~~our~~$ ~~financial~~1,587,433 ~~statements~~ for the three ~~and~~months ~~nine~~ended September 30, 2024. The decrease was primarily attributable to the fact that Neimenggu Province was emerging from the pandemic during the three months ended ~~March~~September 3130, ~~2024~~2023. A large number of customers received services during that quarter that they had earlier paid for but could not receive. This resulted in a surge in revenue during the three months ended September 30, ~~there~~2023. ~~was~~One noother ~~accounting~~important factor influencing revenue in the recent quarter is the ~~estimate~~impact ~~made~~of the economic environment, which ~~was~~has (led to a) ~~subject~~decrease in customer health expenditures. Management believes that the government has recently introduced policies to apromote ~~high~~economic ~~degree~~recovery, ofbut ~~uncertainty~~it ~~and~~may ~~(b)~~take ~~material~~some time for the situation to ~~our~~truly ~~results~~improve. Meanwhile, as we wait for the economy to revive, the Company is implementing plans to improve its operations by adjusting its operational policies.

~~Results~~ Cost of revenue relates solely to our service revenue, and mainly consists of ~~Operations~~our payments to the third-party healthcare service providers who perform healthcare services for our customers. During the three months ended September 30, 2024, our cost of revenue was $32,276, with the result that our gross profit from service revenue was $14,319 (a gross margin of 31%). By comparison, our gross profit from service revenue for the three months ended September 30, 2023 was $109,579, representing 63% of service revenue for that quarter.

~~Three~~When our net service revenue in the three months ~~Months~~ended ~~Ended~~September ~~March~~30, 312024 was combined with commission revenue (for which there is no cost of revenue), we achieved gross profit of $769,072. However, we realized a $62,076 loss from operations for the three months ended September 30, 2024 ~~Compared~~because the Company incurred significant marketing expense in connection with establishing its brand as a new company. The Company will continue to ~~Three~~invest ~~Months~~heavily ~~Ended~~in ~~March~~advertising and ~~31,~~promotion ~~2023~~expenses in the near future as it continues to establish and expand its brand and products and services.

~~The following~~Our ~~table~~operating ~~shows~~expenses ~~key~~consist ~~components~~primarily of ~~the~~advertising and ~~unaudited~~promotion ~~results~~expenses, ofsalaries ~~operations~~and benefits, office expenses, professional fees and depreciation and amortization. Our operating expenses during the three months ended ~~March~~September 3130, 2024 ~~and~~decreased ~~March~~by 31$291, ~~2023~~928, primarily attributable to:

	For the Three Months Ended
	March 31,
	2024			2023			Change
	(Unaudited)			(Unaudited)			$			%
Total revenue	$	1,790,084		$	280,138		$	1,509,946			539	%
Cost of revenue		38,597			118,516			(79,919	)		(67	)%
Gross Profit		1,751,487			161,622			1,589,865			984	%
Total operating expenses		1,032,623			634,143			398,480			63	%
Income (loss) from operations		718,864			(472,521	)		1,191,385			(252	)%
Other income (expense), net		(9,603	)		1,213			(10,816	)		(892	)%
Income (loss) before income taxes		709,261			(471,308	)		1,180,569			(250	)%
Income tax		191,292			-			191,292			n/a
Net Income (Loss)	$	517,969		$	(471,308	)	$	989,277			(210	)%

●

$308,910 in advertising and promotion expenses incurred during the three months ended September 30, 2024, compared to $654,452 recorded during the three months ended September 30, 2023. The decrease was primarily attributable to a tactical decision by Management to reduce marketing expense while we await an economic recovery that will fund an increase in non-essential medical expenditures. Over the longer term, we intend to continue to devote available resources to expanded advertising and promotion expense for the purpose of achieving a broader market.

2● $135,321 in salaries and benefit expenses in the three months ended September 30, 2024, compared to $186,651 during the three months ended September 30, 2023. The decrease in our labor costs was primarily caused by the company decreasing the number of employees due to adjustments in its operational policies.

~~During the~~● ~~three months ended March 31, 2024, our revenue was~~ $1208,~~790,084,~~623 ofin ~~which~~office ~~$53,807~~expenses ~~was~~during ~~attributable to~~ the ~~sale~~three ofmonths ~~healthcare~~ended ~~services and~~September ~~healthcare products~~30, ~~primarily derived from sales of “Immunological Ozonated Autohemotherapy”~~2024, ~~“Meridian-regulating and~~compared ~~Consciousness-restoring~~to ~~Iatrotechnics”, “Assay”, “PRP” and other healthcare services. The remaining~~ $1203,~~736,277~~965 ofduring ~~revenue was commission revenue that arose from a contract~~ the ~~Company~~three ~~made~~months inended ~~June~~September ~~2023~~30, ~~to act as sales agent for a single healthcare provider~~2024. ~~From~~Our ~~June~~office ofexpenses ~~2023,~~in the ~~Company~~three ~~focused~~months ~~its~~ended ~~marketing~~September ~~on the sales of preventive healthcare solutions provided by our contractor. Since the contractor is responsible for providing all services~~30, we2024 ~~recorded~~were ~~our~~roughly ~~portion~~equivalent ofto ~~the~~office ~~customer~~expense ~~payments~~in ~~as a commission on sales of~~ the ~~contractor’s~~three ~~services.~~months Asended ofSeptember ~~March 31~~30, ~~2024~~2023, wedespite ~~operated~~the ~~through~~52% ~~five~~reduction ~~entities: Longduoduo Health Technology, Tianju, Qingguo, Rongbin and Chengheng, which are established~~ in ~~Ordos~~revenue, ~~Ulanqab,~~because ~~Huhhot,~~our ~~Baotou~~business ~~and~~has ~~Ordos~~matured, ~~respectively,~~resulting ~~four of the ten largest cities~~ in ~~Inner~~fixed ~~Mongolia,~~daily ~~China~~expenses.

~~There is~~Our nonet ~~direct~~loss ~~cost~~for ~~that~~the wethree ~~incur~~months ~~when~~ended weSeptember 30, ~~refer~~2024 awas ~~customer~~$59,504, compared to ~~our~~a ~~contractor.~~net ~~Therefore~~income of $294,744 ~~cost~~for ofthe ~~revenue~~three onmonths ~~our~~ended ~~Statements~~September of30, ~~Operations~~2024. For the reasons discussed above, ~~consists~~we ~~entirely~~believe that the company will return to profitability in the next quarter or at the beginning of 2025, as the ~~cost~~government wehas ~~incur~~recently introduced ~~when~~many ~~our~~policies ~~subsidiaries~~to ~~provide~~promote ~~healthcare~~economic ~~services~~recovery. ~~for~~But ~~our~~it ~~customers~~may ~~and~~take some time for the ~~cost~~situation ofto ~~purchasing~~truly improve. Also, the company ~~products~~will intends to improve its operations by adjusting its operational policies.

During the three months ended March 31, 2024, our cost of revenue was $38,597, with the result that our gross profit was $1,781,487, a gross margin of more than 98%. Gross margin at that level was sufficient to operate profitably. However, we realized only $517,969 in income from operations for the three months ended March 31, 2024 because the Company incurred significant marketing expense in connection with establishing its brand as a new company. The Company will continue to invest heavily in advertising and promotion expenses in the near future as it continues to establish and expand its brand and products and services.3

~~Operating~~Our reporting currency is the U.S. dollar. Our ~~expenses~~local ~~consist~~currency, ~~primarily~~the Renminbi (RMB), is our functional currency. Results of ~~advertising~~operations and ~~promotion~~cash ~~expenses,~~flow ~~salaries~~are ~~and~~translated ~~benefits,~~at ~~office~~average ~~expenses~~exchange rates during the period being reported upon, ~~professional~~and ~~fees~~assets and ~~depreciation~~liabilities are translated at the unified exchange rate as quoted by OANDA ~~and~~on ~~amortization~~the balance sheet date. ~~Our~~Translation ~~operating~~adjustments ~~expenses~~resulting ~~during~~from ~~the~~this process are included in other comprehensive income (loss). For the three months ended ~~March~~September 3130, 2024 ~~increased~~and by2023, foreign currency translation adjustments of $~~398~~46,~~480~~989 ~~when~~and ~~compared~~$(1,148), torespectively, have been reported as other comprehensive income (loss) in the ~~three months~~consolidated ~~ended~~statement ~~March~~of ~~31,~~operations ~~2023,~~and ~~primarily~~comprehensive ~~attributable~~income ~~to:~~(loss).

●Liquidity ~~$634,316 in advertising~~ and ~~promotion~~Capital ~~expenses incurred during the three months ended March 31, 2024, compared to $308,990 recorded during the three months ended March 31, 2023.~~Resources

●As ~~$171~~of September 30,~~901~~ 2024, the Company had $849,840 in ~~office~~cash ~~expenses~~and ~~during~~cash equivalents. On the ~~three~~same ~~months~~date, ~~ended~~we ~~March~~had 31a working capital of only $347,732, ~~2024~~because we had received $608,106 ~~compared~~from customers as prepayment for future services and products but used the majority of the deposited sum to pay ongoing expenses. As a result, our September 30, 2024 balance sheet included only $77162,~~501~~593 ~~during~~of ~~the~~prepayments ~~three~~among ~~months~~our ~~ended~~current ~~March~~assets, 31while recording $608,106 ~~2023~~of deferred revenue among our current liabilities. ~~The~~Going ~~increase~~forward, ~~was~~we ~~mainly~~will ~~attributable~~strive to ~~the~~achieve ~~fact~~a better balance of customer deposits and prepayments; but we will achieve that ~~the~~better ~~growth~~balance ofonly ~~business~~when ~~has~~profits ~~led~~from operations and funds from financing are adequate to ansupport ~~increase~~the inexpansion ~~daily~~effort ~~expenses~~that will be necessary for successful operations.

3We anticipate that our future liquidity requirements will arise from the need to fund our growth, pay current obligations and future capital expenditures. The primary sources of funding for such requirements are expected to be cash generated from operations and additional funds from a public offering and/or debt financing. We expect Zhang Liang, our majority shareholder, to continue to provide support in the future, if needed. However, we can provide no assurances that we will be able to generate sufficient cash flows from operations and/or obtain additional financing on terms satisfactory to us, if at all, to remain a going concern.

~~As described~~Cash ~~above, our net income for the three months ended March 31, 2024 was $517,969, compared to a net loss of $471,308 for the three months ended March 31, 2023.~~Flows

~~Our reporting~~The ~~currency~~following isunaudited ~~the~~table ~~U.S.~~summarizes ~~dollar. Our local currency, the Renminbi (RMB), is~~ our ~~functional currency. Results of operations and~~ cash ~~flow are translated at average exchange rates during the period being reported upon, and assets and liabilities are translated at~~ ~~the~~flows ~~unified~~for ~~exchange rate as quoted by OANDA on~~ the ~~balance sheet date. Translation adjustments resulting from this process are included in other comprehensive income (loss). For the~~ three months ended ~~March~~September 3130, 2024 and 2023, foreign currency translation adjustments of $(10,118) and $(7,394), respectively, have been reported as other comprehensive (loss) in the consolidated statement of operations and comprehensive income (loss).

Nine Months Ended March 31, 2024 Compared to Nine Months Ended March 31, 2023

	For the Three Months Ended September 30,
	2024			2023
	(Unaudited)			(Unaudited)			Change
Net cash used in operating activities	$	(534,998	)	$	(383,169	)	$	(151,829	)
Net cash used in investing activities		(56,431	)		(20,849	)		(35,582	)
Effect of exchange rate fluctuation on cash and cash equivalents		37,227			(2,714	)		(39,941	)
Net decrease in cash and cash equivalents		(554,202	)		(406,732	)		(147,470	)
Cash and cash equivalents, beginning of period		1,404,042			1,136,562			267,480
Cash and cash equivalents, end of period	$	849,840		$	729,830		$	120,010

~~The following~~Net ~~table~~Cash ~~shows~~Used ~~key~~in ~~components~~Operating ~~of the unaudited results of operations during the nine months ended March 31, 2024 and 2023:~~ Activities

	For the Nine Months Ended
	March 31,
	2024			2023			Change
	(Unaudited)			(Unaudited)			$			%
Total revenue	$	5,718,060		$	759,895		$	4,958,165			652	%
Cost of revenue		143,347			299,780			(156,433	)		(52	)%
Gross Profit		5,574,713			460,115			5,114,598			1112	%
Total operating expenses		4,026,082			1,424,759			2,601,323			183	%
Income (loss) from operations		1,584,631			(964,644	)		2,513,275			(261	)%
Other income (expense), net		(144,825	)		1,744			(146,569	)		(8404	)%
Income (loss) before income taxes		1,403,806			(962,900	)		2,366,706			(246	)%
Income tax		408,265			-			408,265			n/a
Net Income (Loss)	$	995,541		$	(962,900	)	$	1,958,441			(203	)%

For the three months ended September 30, 2024, we used $534,998 cash in our operating activities, compared to $383,169 used in operating activities for the three months ended September 30, 2023. Our use of cash in operating activities substantially exceeded our net loss of $59,504 for the three month period, primarily because we provided services valued at $128,263 to customers who had paid for the services in prior periods, thus reducing our deferred revenue balance, and we used $198,911 to reduce accounts payable.

~~During the~~Net ~~nine~~Cash ~~months~~Used ended March 31, 2024, our revenue was total $5,718,060, of which $327,653 was attributable to the sale of healthcare services and healthcare products, primarily derived from sales of “Immunological Ozonated Autohemotherapy”, “Meridian-regulating and Consciousness-restoring Iatrotechnics”, “Assay”, “PRP” and other healthcare services. The remaining $5,390,407 of revenue was commission revenue that arose from a contract the Company made in ~~June~~Investing 2023 to act as sales agent for a single healthcare provider. From June of 2023, the Company focused its marketing on the sales of preventive healthcare solutions provided by our contractor. Since the contractor is responsible for providing all services, we recorded our portion of the customer payments as a commission on sales of the contractor’s services. As of March 31, 2024, we operate through five entities: Longduoduo Health Technology, Tianju, Qingguo, Rongbin and Chengheng, which are established in Ordos, Ulanqab, Huhhot, Baotou and Ordos, respectively, four of the ten largest cities in Inner Mongolia, China.Activities

~~There is~~Net nocash ~~direct~~used ~~cost~~in ~~that~~investing weactivities ~~incur when we refer a customer to our contractor. Therefore, cost of revenue on our Statements of Operations consists entirely of the cost we incur when our subsidiaries provide healthcare services~~ for ~~our customers and~~ the ~~cost of purchasing~~ ~~products.~~three ~~During the nine~~ months ended ~~March~~September 3130, 2024, ~~our cost of revenue~~ was $~~143~~56,~~347~~431, ~~with~~compared ~~the result that our gross profit was $5,574,713, a gross margin of more than 97%. Gross margin at that level was sufficient~~ to ~~operate profitably. However, we realized only~~ $~~995~~20,~~541 in~~849 ~~income from operations~~ for the ~~nine~~three months ended ~~March~~September 3130, 2024. ~~because~~In ~~the~~both ~~Company incurred significant marketing expense in connection~~periods, ~~with~~the ~~establishing~~cash ~~its~~was ~~brand~~used asfor ~~a new company. The Company will continue to invest heavily in advertising and promotion expenses in~~ the ~~near~~ ~~future~~purchase asof itfixed ~~continues~~assets ~~to establish~~ and ~~expand~~office ~~its brand and products and services~~decoration.

Operating expenses consist primarily of advertising and promotion expenses, salaries and benefits, office expenses, professional fees and depreciation and amortization. Our operating expenses during the nine months ended March 31, 2024 increased by $2,601,323, primarily attributable to:4

~~● $2~~Trends,~~667,233~~ inEvents ~~advertising~~ and ~~promotion expenses incurred during the nine months ended March 31, 2024, compared to $539,836 recorded during the nine months ended March 31, 2023.~~Uncertainties

●The ~~$494~~U.S. government,~~416~~ including the SEC, has made statements and taken actions that have led to changes in ~~salaries~~relations between the U.S. and ~~benefit~~China, ~~expenses~~and will impact companies with connections to the United States or China. Those actions by the U.S. government included imposing several rounds of tariffs affecting certain products manufactured in China and imposing sanctions and restrictions in relation to China. Actions by the ~~nine~~SEC ~~months~~included ~~ended~~issuing ~~March~~statements 31indicating that it would make enhanced review of companies with significant China-based operations. It is unknown whether and to what extent new legislation, ~~2024~~executive orders, ~~compared~~tariffs, laws or regulations will be adopted, or the effect that any such actions would have on U.S.-domiciled companies with significant connections to ~~$476~~China,~~436~~ ~~during~~our industry or on us. Any unfavorable government policies on cross-border relations, including increased scrutiny on companies with significant China-based operations, capital controls or tariffs, may affect our ability to raise capital and the ~~nine~~market ~~months~~price ~~ended~~of ~~March~~our 31shares. If any new legislation, ~~2023~~executive orders, tariffs, laws and/or regulations are implemented, if existing trade agreements are renegotiated or if the U.S. or Chinese governments take retaliatory actions due to the recent U.S.-China tensions, such changes could have an adverse effect on our business, financial condition and results of operations, our ability to raise capital and the market price of our shares. Changes in United States and China relations and/or regulations may adversely impact our business, our operating results, our ability to raise capital and the market price of our shares.

●Other ~~$599,169~~than inthe ~~office~~factors ~~expenses~~listed ~~during~~above ~~the~~we ~~nine~~do ~~months~~not ~~ended~~know ~~March~~of ~~31,~~any ~~2024~~trends, ~~compared~~events or touncertainties ~~$228,133~~that ~~during~~have ~~the~~had ~~nine~~or ~~months~~are ~~ended~~reasonably ~~March~~expected ~~31, 2023. The increase was mainly attributable~~ to ~~the~~have ~~fact~~a ~~that~~material ~~the~~impact ~~growth~~on ofour ~~business~~net ~~has~~sales ~~led~~or torevenues anor ~~increase~~income infrom ~~daily expenses~~continuing operations.

4Recent Accounting Pronouncements

AsThere were no recent accounting pronouncements ~~described~~that ~~above,~~we ~~our~~expect ~~net~~to ~~income~~have ~~for~~a material effect on the ~~nine~~Company’s ~~months~~financial ~~ended~~position ~~March~~or ~~31,~~results ~~2024~~of ~~was~~operations. ~~$995,541,~~Please ~~compared~~refer to aNote ~~net~~2 ~~loss~~ of our ~~$962,900~~consolidated ~~for~~financial ~~the~~statements ~~nine months~~included ~~ended~~in ~~March~~this ~~31,~~annual ~~2023~~report.

~~Our reporting~~Item ~~currency is the U~~3.S. ~~dollar.~~Quantitative ~~Our local currency, the Renminbi (RMB), is our functional currency. Results of operations~~ and ~~cash~~ ~~flow~~Qualitative ~~are~~Disclosures ~~translated~~about atMarket ~~average exchange rates during the period being reported upon, and assets and liabilities are translated at the unified exchange rate as quoted by OANDA on the balance sheet date~~Risk. Translation adjustments resulting from this process are included in other comprehensive income (loss). For the nine months ended March 31, 2024 and 2023, foreign currency translation adjustments of $(4,761) and $14,963, respectively, have been reported as other comprehensive income (loss) in the consolidated statement of operations and comprehensive income (loss).

~~Liquidity and~~Not ~~Capital Resources~~applicable.

~~As of~~Item ~~March 31, 2024, the Company had $1,883,261 in cash and cash equivalents~~4. OnControls the same date, we had a working capital of only $94,687, primarily because we had received $1,135,696 from customers as deposits for future services but used the majority of the deposited sum to pay ongoing expenses and ~~so had only $225,725 in prepayments on our March 31, 2024 balance sheet~~Procedures. Going forward, we will strive to achieve a better balance of customer deposits and prepayments; but we will achieve that better balance only when profits from operations and funds from financing are adequate to support the expansion effort that will be necessary for successful operations.

~~We anticipate~~Evaluation ~~that our future liquidity requirements will arise from the need to fund our growth, pay current obligations and future capital expenditures. The primary sources~~ of ~~funding~~Disclosure ~~for~~Controls ~~such requirements are expected to be cash generated from operations~~ and raising additional funds from a public offering and/or debt financing. However, we can provide no assurances that we will be able to generate sufficient cash flows from operations and/or obtain additional financing on terms satisfactory to us, if at all.Procedures

~~Cash~~Our management maintains disclosure controls and ~~Flows~~procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that the material information required to be disclosed by us in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

~~The~~Under the supervision and with the participation ~~following~~of ~~unaudited~~our ~~table~~management ~~summarizes~~team, including our ~~cash~~Chief ~~flows~~Executive ~~for~~Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the ~~nine~~Securities ~~months~~Exchange ~~ended~~Act of ~~March~~1934, 31as amended, as of September 30, 2024. Based on this evaluation, we concluded that our disclosure controls and ~~2023.~~procedures have the following material weaknesses:

	For the Nine Months Ended March 31,
	2024			2023
	(Unaudited)			(Unaudited)			Change
Net cash provided by operating activities	$	988,489		$	507,942		$	489,936
Net cash used in investing activities		(248,874	)		(75,353	)		(173,521	)
Net cash used in financing activities		-			(138,450	)		138,450
Effect of exchange rate fluctuation on cash and cash equivalents		7,084			(6,189	)		3,884
Net increase in cash and cash equivalents		746,699			287,950			458,749
Cash and cash equivalents, beginning of period		1,136,562			356,672			779,890
Cash and cash equivalents, end of period	$	1,883,261		$	644,622		$	1,283,639

●

The relatively small number of employees who are responsible for accounting functions prevents us from segregating duties within our internal control system.

~~Net Cash~~● ~~Provided~~Our byinternal ~~Operating~~financial ~~Activities~~staff lack expertise in identifying and addressing complex accounting issues under U.S. Generally Accepted Accounting Principles.

~~For the~~● ~~nine~~Our ~~months~~Chief ~~ended~~Financial ~~March~~Officer ~~31,~~is ~~2024,~~not ~~our~~familiar ~~operating~~with ~~activities provided $988,4899 cash, compared to $507,942 provided by operating activities during~~ the ~~nine~~accounting ~~months~~and ~~ended~~reporting ~~March~~requirements ~~31, 2023. The cash inflow that we realized during the nine months ended March 31, 2024 was primarily due to recording net income~~ of ~~$995,541~~a ~~and~~U.S. ~~receiving~~public ~~$546,243 in deposits by customers for future services, from which we used $417,694 to reduce accounts payable and $105,225 to pay off loans made to us by related parties~~company.

~~Net Cash~~● ~~Used~~We inhave ~~Investing~~not ~~Activities~~developed sufficient documentation concerning our existing financial processes, risk assessment and internal controls.

~~Net cash~~Based ~~used~~on intheir ~~investing~~evaluation, ~~activities~~our ~~for~~Chief ~~the~~Executive Officer ~~nine~~and ~~months~~Chief ~~ended~~Financial ~~March~~Officer ~~31,~~concluded ~~2024~~that ~~was $248,874, compared to $75,353 for~~ the ~~nine~~Company’s ~~months~~system ~~ended March~~of ~~31,~~disclosure ~~2023.~~controls ~~The~~and ~~cash~~procedures was ~~used~~not ineffective as ~~both~~of ~~periods~~September 30, 2024 for the ~~purchase~~purposes ofdescribed ~~fixed~~in ~~assets~~this paragraph.

~~Net Cash~~Changes ~~Used~~ in ~~Financing~~Internal ~~Activities~~Control over Financial Reporting

~~Net cash~~During ~~provided~~the byperiod ~~financing~~covered ~~activities~~by ~~for~~this ~~the~~report, ~~nine~~there has ~~months~~been ~~ended~~no ~~March~~change ~~31,~~in ~~2024~~our ~~was~~internal ~~$nil,~~control ~~compared~~over tofinancial ~~$138,450~~reporting ~~for~~that ~~the~~has ~~nine~~materially ~~months~~affected ~~ended March~~or ~~31,~~is ~~2023,~~reasonably ~~which~~likely ~~was~~to ~~the~~materially affect ~~proceeds~~our ofinternal acontrol ~~loan~~over ~~from~~financial ~~a third party~~reporting.

~~Trends, Events~~PART ~~and~~II ~~Uncertainties~~– OTHER INFORMATION

~~The COVID-19~~Item ~~pandemic has had a significant adverse impact and created many uncertainties related to our business, and we expect that it will continue to do so~~1. ~~The~~Legal ~~Company is experiencing challenges in sales, which have increased the Company’s financial uncertainty~~Proceedings. Our future business outlook and expectations are very uncertain due to the impact of the COVID-19 pandemic and are very difficult to quantify. It is difficult to assess or predict the impact of this unprecedented event on our business, financial results or financial condition. Factors that will impact the extent to which the COVID-19 pandemic affects our business, financial results and financial condition include: the duration, spread and severity of the pandemic; the actions taken to contain the virus or treat its impact, including government actions to mitigate the economic impact of the pandemic; and how quickly and to what extent normal economic and operating conditions can resume, including whether any future outbreaks interrupt the economic recovery.

~~The U.S.~~From ~~government,~~time ~~including~~to ~~the SEC~~time, ~~has~~we ~~made~~may ~~statements~~become ~~and~~involved ~~taken actions that have led to changes~~ in ~~relations between the U.S. and~~legal ~~China,~~proceedings ~~and~~or ~~will~~be ~~impact~~subject ~~companies with connections~~ to ~~the~~claims ~~United~~arising ~~States or China. Those actions by the U.S. government included imposing several rounds of tariffs affecting certain products manufactured~~ in ~~China and imposing sanctions and restrictions in relation to China. Actions by~~ the ~~SEC~~ordinary ~~included~~course ~~issuing statements indicating that it would make enhanced review~~ of ~~companies~~our ~~with significant China-based operations~~business. ItWe isare ~~unknown~~not ~~whether~~presently ~~and~~a party to ~~what~~any ~~extent~~legal ~~new legislation, executive orders, tariffs, laws or regulations will be adopted,~~proceedings ~~or the effect~~ that ~~any~~in such actions would have on U.S.-domiciled companies with significant connections to China, our industry or on us. Any unfavorable government policies on cross-border relations, including increased scrutiny on companies with significant China-based operations, capital controls or tariffs, may affect our ability to raise capital and the ~~market~~opinion ~~price~~ of our ~~shares. If any new legislation~~management, ~~executive~~ ~~orders,~~if ~~tariffs,~~determined ~~laws~~adversely ~~and/or~~to ~~regulations are implemented~~us, ifwould ~~existing~~individually ~~trade agreements are renegotiated~~ or iftaken ~~the~~together ~~U.S. or Chinese governments take retaliatory actions due to the recent U.S.-China tensions, such changes could~~ have ana material adverse effect on our business, ~~financial~~ ~~condition~~operating ~~and~~ results, offinancial ~~operations~~condition, ~~our ability to raise capital and the market price of our shares. Changes in United States and China relations and/~~or ~~regulations~~cash ~~may adversely impact our business, our operating results, our ability to raise capital and the market price of our shares~~flows.

~~Other than~~Item ~~the~~1A. ~~factors~~Risk ~~listed above we do not know of any trends, events or uncertainties that have had or are reasonably expected to have a material impact on our net sales or revenues or income from continuing operations~~Factors.

~~Recent~~There have been no material changes from the risk ~~Accounting~~factors ~~Pronouncements~~included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2024, as filed with the SEC on October 15, 2024.

~~There were~~Item no2. ~~recent~~Unregistered ~~accounting~~Sale ~~pronouncements that we expect to have a material effect on the Company’s financial position or results~~ of ~~operations.~~Equity ~~Please~~Securities ~~refer~~and toUse ~~Note 2~~ of ~~our consolidated financial statements included in this annual report~~Proceeds.

6During the quarter ended September 30, 2024, the Company did not complete any unregistered sales of equity securities.

~~Item~~The Company did not repurchase any of its equity 3.securities ~~Quantitative~~that ~~and~~were ~~Qualitative~~registered ~~Disclosures~~under ~~about~~Section ~~Market~~12 ~~Risk~~of the Securities Act during the quarter ended September 30, 2024.

~~Not applicable~~Item 3. Defaults upon Senior Securities.

~~Item 4.~~Not ~~Controls and Procedures.~~applicable

~~Evaluation of~~Item ~~Disclosure~~4. ~~Controls~~Mine ~~and~~Safety ~~Procedures~~Disclosure

~~Our management~~Not maintains disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), that are designed to provide reasonable assurance that the material information required to be disclosed by us in our periodic reports filed or submitted under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and formsapplicable. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures.

~~Under the~~Item supervision and with the participation of our management team, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of our disclosure controls and procedures, as such term is defined under Rule 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as amended, as of March 31, 20245. ~~Based~~Other ~~on this evaluation, we concluded that our disclosure controls and procedures have the following material weaknesses:~~Information.

●During ~~The~~the ~~relatively~~quarter ~~small~~ended ~~number~~September of30, ~~employees~~2024, ~~who~~no ~~are~~director ~~responsible~~or ~~for~~officer adopted or terminated any Rule ~~accounting~~10b5-1 ~~functions~~trading ~~prevents~~arrangement usor ~~from~~non-Rule ~~segregating~~10b5-1 ~~duties~~trading ~~within~~arrangement, ~~our~~as ~~internal~~each ~~control~~term ~~system~~is defined in Item 408(a) of Regulation S-K.

●Item ~~Our internal financial staff lack expertise in identifying and addressing complex accounting issues under U~~6.S. ~~Generally Accepted Accounting Principles.~~Exhibits

●INDEX ~~Our~~TO ~~Chief Financial Officer is not familiar with the accounting and reporting requirements of a U.S. public company.~~EXHIBITS

● We have not developed sufficient documentation concerning our existing financial processes, risk assessment and internal controls.

Exhibit No.		Description of Exhibit
31.1		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

Based on their evaluation, our Chief Executive Officer and Chief Financial Officer concluded that the Company’s system of disclosure controls and procedures was not effective as of March 31, 2024 for the purposes described in this paragraph.6

~~Changes in Internal Control over Financial Reporting~~SIGNATURES

~~During the~~Pursuant ~~period~~to ~~covered~~the byrequirements ~~this~~of ~~report,~~the ~~there~~Securities Exchange ~~has~~Act ~~been~~of no1934, ~~change~~the inregistrant ~~our~~has ~~internal~~duly ~~control~~caused ~~over~~this ~~financial~~report ~~reporting~~to ~~that~~be ~~has~~signed ~~materially~~on ~~affected or~~its isbehalf ~~reasonably~~by ~~likely~~the toundersigned ~~materially~~thereunto ~~affect~~duly ~~our internal control over financial reporting~~authorized.

7LONGDUODUO COMPANY LIMITED

PART II – OTHER INFORMATION

Signature	Title	Date

/s/ Zhou Hongxiao	Chief Executive Officer	November 14, 2024
Zhou Hongxiao	(Principal Executive Officer)

/s/ Kang Liping	Chief Financial Officer	November 14, 2024
Kang Liping	(Principal Financial and Accounting Officer)

~~Item 1. Legal Proceedings.~~7

~~From~~ ~~time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We~~ ~~are not presently a party to any legal proceedings that in the opinion of our management, if determined adversely to~~ false --06-30 Q1 2025 0001892316 0001892316 2024-07-01 2024-09-30 0001892316 2024-11-14 0001892316 2024-09-30 0001892316 2024-06-30 0001892316 us~~, would individually~~-gaap:RelatedPartyMember ~~or taken together have a material adverse effect on our business, operating results, financial condition, or cash flows.~~ 2024-09-30 0001892316 us-gaap:RelatedPartyMember 2024-06-30 0001892316 us-gaap:ServiceMember 2024-07-01 2024-09-30 0001892316 us-gaap:ServiceMember 2023-07-01 2023-09-30 0001892316 lddc:CommissionRevenueMember 2024-07-01 2024-09-30 0001892316 lddc:CommissionRevenueMember 2023-07-01 2023-09-30 0001892316 2023-07-01 2023-09-30 0001892316 us-gaap:CommonStockMember 2023-06-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001892316 us-gaap:RetainedEarningsMember 2023-06-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001892316 us-gaap:ParentMember 2023-06-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-06-30 0001892316 2023-06-30 0001892316 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001892316 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001892316 us-gaap:ParentMember 2023-07-01 2023-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001892316 us-gaap:CommonStockMember 2023-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001892316 us-gaap:RetainedEarningsMember 2023-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001892316 us-gaap:ParentMember 2023-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-09-30 0001892316 2023-09-30 0001892316 us-gaap:CommonStockMember 2024-06-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001892316 us-gaap:RetainedEarningsMember 2024-06-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0001892316 us-gaap:ParentMember 2024-06-30 0001892316 us-gaap:NoncontrollingInterestMember 2024-06-30 0001892316 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001892316 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-01 2024-09-30 0001892316 us-gaap:ParentMember 2024-07-01 2024-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001892316 us-gaap:CommonStockMember 2024-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001892316 us-gaap:RetainedEarningsMember 2024-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0001892316 us-gaap:ParentMember 2024-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2024-09-30 0001892316 2023-09-21 2023-09-21 0001892316 lddc:LongduoduoCompanyLimitedMember 2021-10-26 2021-10-26 0001892316 lddc:LongduoduoCompanyLimitedMember 2021-10-26 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember 2021-08-16 0001892316 lddc:QingguoMember 2020-09-08 0001892316 lddc:RongbinMember 2021-03-18 0001892316 lddc:ChenghengMember 2021-04-09 0001892316 lddc:TianjuMember 2021-07-05 0001892316 2022-07-01 2023-06-30 0001892316 2023-07-01 2024-06-30 0001892316 lddc:LongduoduoCompanyLimitedMember 2024-07-01 2024-09-30 0001892316 lddc:LongduoduoCompanyLimitedMember 2024-09-30 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember 2024-07-01 2024-09-30 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember 2024-09-30 0001892316 lddc:InnerMongoliaQingguoHealthConsultingCompanyLimitedMember 2024-07-01 2024-09-30 0001892316 lddc:InnerMongoliaQingguoHealthConsultingCompanyLimitedMember 2024-09-30 0001892316 lddc:InnerMongoliaRongbinHealthConsultingCompanyLimitedMember 2024-07-01 2024-09-30 0001892316 lddc:InnerMongoliaRongbinHealthConsultingCompanyLimitedMember 2024-09-30 0001892316 lddc:InnerMongoliaChenghengHealthConsultingCompanyLimitedMember 2024-07-01 2024-09-30 0001892316 lddc:InnerMongoliaChenghengHealthConsultingCompanyLimitedMember 2024-09-30 0001892316 lddc:InnerMongoliaTianjuHealthConsultingCompanyLimitedMember 2024-07-01 2024-09-30 0001892316 lddc:InnerMongoliaTianjuHealthConsultingCompanyLimitedMember 2024-09-30 0001892316 currency:CNY lddc:AssetsAndLiabilitiesMember 2024-09-30 0001892316 currency:USD lddc:AssetsAndLiabilitiesMember 2024-09-30 0001892316 currency:CNY lddc:AssetsAndLiabilitiesMember 2023-09-30 0001892316 currency:USD lddc:AssetsAndLiabilitiesMember 2023-09-30 0001892316 currency:CNY lddc:RevenueAndExpensesMember 2024-09-30 0001892316 currency:USD lddc:RevenueAndExpensesMember 2024-09-30 0001892316 currency:CNY lddc:RevenueAndExpensesMember 2023-09-30 0001892316 currency:USD lddc:RevenueAndExpensesMember 2023-09-30 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierAMember 2024-07-01 2024-09-30 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierAMember 2023-07-01 2023-09-30 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierBMember 2024-07-01 2024-09-30 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierBMember 2023-07-01 2023-09-30 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierCMember 2024-07-01 2024-09-30 0001892316 us-gaap:CostOfGoodsTotalMember us-gaap:SupplierConcentrationRiskMember lddc:SupplierCMember 2023-07-01 2023-09-30 0001892316 us-gaap:OfficeEquipmentMember 2024-09-30 0001892316 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2024-09-30 0001892316 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2024-09-30 0001892316 us-gaap:SoftwareDevelopmentMember 2024-09-30 0001892316 us-gaap:OfficeEquipmentMember 2024-06-30 0001892316 us-gaap:LeaseholdImprovementsMember 2024-09-30 0001892316 us-gaap:LeaseholdImprovementsMember 2024-06-30 0001892316 lddc:MrZhangLiangMember 2023-11-29 2023-11-29 0001892316 lddc:ZhangLiangMember 2024-09-30 0001892316 lddc:ZhangLiangMember 2024-06-30 0001892316 country:US 2024-07-01 2024-09-30 0001892316 country:HK 2024-07-01 2024-09-30 0001892316 country:CN lddc:LongduoduoHealthTechnologyAndSubsidiariesMember 2024-07-01 2024-09-30 0001892316 country:CN 2024-09-30 0001892316 country:CN 2023-09-30 0001892316 lddc:LongduoduoHealthTechnologyAndSubsidiariesMember 2024-07-01 2024-09-30 0001892316 country:CN 2024-07-01 2024-09-30 0001892316 country:CN 2023-07-01 2023-09-30 0001892316 country:US 2023-07-01 2023-09-30 0001892316 lddc:USFederalMember 2024-07-01 2024-09-30 0001892316 us-gaap:StateAdministrationOfTaxationChinaMember 2024-07-01 2024-09-30 0001892316 lddc:DingJunMember 2024-06-01 0001892316 lddc:DingJunMember 2024-06-01 2024-06-01 0001892316 lddc:LiuLibaoMember 2024-03-10 0001892316 lddc:LiuLibaoMember 2024-03-10 2024-03-10 0001892316 lddc:HanRuijunMember 2024-04-01 0001892316 lddc:HanRuijunMember 2024-04-01 2024-04-01 0001892316 lddc:MongoliaChuangfuhuiEnterpriseManagementCoLtdMember 2024-08-31 0001892316 lddc:MongoliaChuangfuhuiEnterpriseManagementCoLtdMember 2024-08-31 2024-08-31 0001892316 srt:MinimumMember 2024-09-30 0001892316 srt:MaximumMember 2024-09-30 0001892316 srt:MinimumMember lddc:BorrowingRateMember 2024-07-01 2024-09-30 0001892316 srt:MaximumMember lddc:BorrowingRateMember 2024-07-01 2024-09-30 0001892316 lddc:KangLipingMember srt:ChiefFinancialOfficerMember 2023-02-20 2023-02-20 0001892316 2023-09-21 0001892316 us-gaap:CommonStockMember 2023-09-21 2023-09-21 0001892316 lddc:QingguoMember 2024-09-30 0001892316 lddc:ChenghengMember 2024-09-30 0001892316 lddc:RongbinMember 2024-09-30 0001892316 lddc:TianjuMember 2024-09-30 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CNY iso4217:HKD utr:sqm iso4217:NPR

Item 1A. Risk Factors.

There have been no material changes from the risk factors included in the Company’s Annual Report on Form 10-K for the year ended June 30, 2023, as filed with the SEC on November 14, 2023.

Item 2. Unregistered Sale of Equity Securities and Use of Proceeds.

During the quarter ended March 31, 2024, the Company did not complete any unregistered sales of equity securities.

The Company did not repurchase any of its equity securities that were registered under Section 12 of the Securities Act during the quarter ended March 31, 2024.

Item 3. Defaults upon Senior Securities.

Not applicable

Item 4. Mine Safety Disclosure

Not applicable.

Item 5. Other Information.

During the quarter ended March 31, 2024, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

Item 6. Exhibits

INDEX TO EXHIBITS

Exhibit No.		Description of Exhibit
31.1		Certification of Chief Executive Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Certification of Chief Financial Officer pursuant to Securities Exchange Act Rule 13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2		Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document.
101.SCH		Inline XBRL Taxonomy Extension Schema Document.
101.CAL		Inline XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF		Inline XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB		Inline XBRL Taxonomy Extension Label Linkbase Document.
101.PRE		Inline XBRL Taxonomy Extension Presentation Linkbase Document.
104		Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

LONGDUODUO COMPANY LIMITED

Signature	Title	Date
/s/ Zhou Hongxiao	Chief Executive Officer	May 9, 2024
Zhou Hongxiao	(Principal Executive Officer)
/s/ Kang Liping	Chief Financial Officer	May 9, 2024
Kang Liping	(Principal Financial and Accounting Officer)

NONE 0.014 0.017 0.029 0.031 30000008 30000008 30005016 30005016 30000008 30005016 0.014 0.017 30000008 30005016 0.029 0.031 false --06-30 Q3 0001892316 0001892316 2023-07-01 2024-03-31 0001892316 2024-05-09 0001892316 2024-03-31 0001892316 2023-06-30 0001892316 us-gaap:RelatedPartyMember 2024-03-31 0001892316 us-gaap:RelatedPartyMember 2023-06-30 0001892316 2024-01-01 2024-03-31 0001892316 2023-01-01 2023-03-31 0001892316 2022-07-01 2023-03-31 0001892316 us-gaap:CommonStockMember 2022-06-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001892316 us-gaap:RetainedEarningsMember 2022-06-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001892316 us-gaap:ParentMember 2022-06-30 0001892316 us-gaap:NoncontrollingInterestMember 2022-06-30 0001892316 2022-06-30 0001892316 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001892316 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001892316 us-gaap:ParentMember 2022-07-01 2022-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2022-07-01 2022-09-30 0001892316 2022-07-01 2022-09-30 0001892316 us-gaap:CommonStockMember 2022-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001892316 us-gaap:RetainedEarningsMember 2022-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001892316 us-gaap:ParentMember 2022-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2022-09-30 0001892316 2022-09-30 0001892316 us-gaap:CommonStockMember 2022-10-01 2022-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2022-10-01 2022-12-31 0001892316 us-gaap:RetainedEarningsMember 2022-10-01 2022-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-01 2022-12-31 0001892316 us-gaap:ParentMember 2022-10-01 2022-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2022-10-01 2022-12-31 0001892316 2022-10-01 2022-12-31 0001892316 us-gaap:CommonStockMember 2022-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001892316 us-gaap:RetainedEarningsMember 2022-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001892316 us-gaap:ParentMember 2022-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2022-12-31 0001892316 2022-12-31 0001892316 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001892316 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001892316 us-gaap:ParentMember 2023-01-01 2023-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0001892316 us-gaap:CommonStockMember 2023-03-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001892316 us-gaap:RetainedEarningsMember 2023-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001892316 us-gaap:ParentMember 2023-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2023-03-31 0001892316 2023-03-31 0001892316 us-gaap:CommonStockMember 2023-06-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001892316 us-gaap:RetainedEarningsMember 2023-06-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001892316 us-gaap:ParentMember 2023-06-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-06-30 0001892316 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001892316 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001892316 us-gaap:ParentMember 2023-07-01 2023-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-07-01 2023-09-30 0001892316 2023-07-01 2023-09-30 0001892316 us-gaap:CommonStockMember 2023-09-30 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001892316 us-gaap:RetainedEarningsMember 2023-09-30 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001892316 us-gaap:ParentMember 2023-09-30 0001892316 us-gaap:NoncontrollingInterestMember 2023-09-30 0001892316 2023-09-30 0001892316 us-gaap:CommonStockMember 2023-10-01 2023-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-10-01 2023-12-31 0001892316 us-gaap:RetainedEarningsMember 2023-10-01 2023-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-01 2023-12-31 0001892316 us-gaap:ParentMember 2023-10-01 2023-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2023-10-01 2023-12-31 0001892316 2023-10-01 2023-12-31 0001892316 us-gaap:CommonStockMember 2023-12-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001892316 us-gaap:RetainedEarningsMember 2023-12-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001892316 us-gaap:ParentMember 2023-12-31 0001892316 us-gaap:NoncontrollingInterestMember 2023-12-31 0001892316 2023-12-31 0001892316 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001892316 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0001892316 us-gaap:ParentMember 2024-01-01 2024-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001892316 us-gaap:CommonStockMember 2024-03-31 0001892316 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001892316 us-gaap:RetainedEarningsMember 2024-03-31 0001892316 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0001892316 us-gaap:ParentMember 2024-03-31 0001892316 us-gaap:NoncontrollingInterestMember 2024-03-31 0001892316 2021-10-26 0001892316 lddc:LongduoduoCompanyLimitedMember 2021-10-26 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember 2021-08-16 0001892316 lddc:QingguoMember 2020-09-08 0001892316 lddc:RongbinMember 2021-03-18 0001892316 lddc:ChenghengMember 2021-04-09 0001892316 lddc:TianjuMember 2021-07-05 0001892316 2022-07-01 2023-06-30 0001892316 2021-07-01 2022-06-30 0001892316 us-gaap:SalesReturnsAndAllowancesMember 2023-07-01 2024-03-31 0001892316 us-gaap:SalesReturnsAndAllowancesMember 2022-07-01 2023-06-30 0001892316 us-gaap:SalesReturnsAndAllowancesMember 2022-07-01 2023-03-31 0001892316 lddc:LongduoduoCompanyLimitedMember country:HK 2023-07-01 2024-03-31 0001892316 lddc:LongduoduoHealthTechnologyCompanyLimitedMember country:CN 2023-07-01 2024-03-31 0001892316 lddc:InnerMongoliaQingguoHealthConsultingCompanyLimitedMember country:CN 2023-07-01 2024-03-31 0001892316 lddc:InnerMongoliaRongbinHealthConsultingCompanyLimitedMember country:CN 2023-07-01 2024-03-31 0001892316 lddc:InnerMongoliaChenghengHealthConsultingCompanyLimitedMember country:CN 2023-07-01 2024-03-31 0001892316 lddc:InnerMongoliaTianjuHealthConsultingCompanyLimitedMember country:CN 2023-07-01 2024-03-31 0001892316 lddc:PeriodEndExchangeRateMember lddc:USDToRMBMember 2024-03-31 0001892316 lddc:PeriodEndExchangeRateMember 2024-03-31 0001892316 lddc:PeriodEndExchangeRateMember lddc:USDToRMBMember 2023-03-31 0001892316 lddc:PeriodEndExchangeRateMember 2023-03-31 0001892316 lddc:PeriodWeightedAverageMember lddc:USDToRMBMember 2024-03-31 0001892316 lddc:PeriodWeightedAverageMember 2024-03-31 0001892316 lddc:PeriodWeightedAverageMember lddc:USDToRMBMember 2023-03-31 0001892316 lddc:PeriodWeightedAverageMember 2023-03-31 0001892316 lddc:SupplierAMember 2023-07-01 2024-03-31 0001892316 lddc:SupplierAMember 2022-07-01 2023-03-31 0001892316 lddc:SupplierBMember 2023-07-01 2024-03-31 0001892316 lddc:SupplierBMember 2022-07-01 2023-03-31 0001892316 lddc:SupplierCMember 2023-07-01 2024-03-31 0001892316 lddc:SupplierCMember 2022-07-01 2023-03-31 0001892316 lddc:SupplierDMember 2023-07-01 2024-03-31 0001892316 lddc:SupplierDMember 2022-07-01 2023-03-31 0001892316 srt:MinimumMember us-gaap:OfficeEquipmentMember 2024-03-31 0001892316 srt:MaximumMember us-gaap:OfficeEquipmentMember 2024-03-31 0001892316 srt:MinimumMember us-gaap:LeaseholdImprovementsMember 2024-03-31 0001892316 srt:MaximumMember us-gaap:LeaseholdImprovementsMember 2024-03-31 0001892316 us-gaap:SoftwareDevelopmentMember 2024-03-31 0001892316 2024-02-08 0001892316 2024-02-08 2024-02-08 0001892316 lddc:MrZhangLiangMember 2023-11-29 2023-11-29 0001892316 lddc:ZhangLiangMember 2023-07-01 2024-03-31 0001892316 lddc:ZhangLiangMember 2022-07-01 2023-06-30 0001892316 lddc:ZhouHongxiaoMember 2023-07-01 2024-03-31 0001892316 lddc:ZhouHongxiaoMember 2022-07-01 2023-06-30 0001892316 country:US 2023-07-01 2024-03-31 0001892316 country:HK 2023-07-01 2024-03-31 0001892316 country:CN lddc:LongduoduoHealthTechnologyAndSubsidiariesMember 2023-07-01 2024-03-31 0001892316 country:CN 2024-03-31 0001892316 country:CN 2023-07-01 2024-03-31 0001892316 country:CN 2022-07-01 2023-03-31 0001892316 country:US 2022-07-01 2023-03-31 0001892316 lddc:USFederalMember 2023-07-01 2024-03-31 0001892316 us-gaap:StateAdministrationOfTaxationChinaMember 2023-07-01 2024-03-31 0001892316 2021-04-01 2021-04-30 0001892316 2022-05-27 2022-05-27 0001892316 2022-05-27 0001892316 2022-07-02 2022-07-02 0001892316 2023-04-04 2023-04-04 0001892316 us-gaap:SubsequentEventMember 2024-04-01 2024-04-01 0001892316 2023-08-31 2023-08-31 0001892316 srt:ChiefFinancialOfficerMember lddc:KangLipingMember 2023-02-20 0001892316 lddc:QingguoMember 2024-03-31 0001892316 lddc:ChenghengMember 2024-03-31 0001892316 lddc:RongbinMember 2024-03-31 0001892316 lddc:TianjuMember 2024-03-31 0001892316 lddc:NonControllingInterestsMember 2024-03-31 0001892316 lddc:NonControllingInterestsMember 2023-06-30 0001892316 lddc:NonControllingInterestsMember 2024-01-01 2024-03-31 0001892316 lddc:NonControllingInterestsMember 2023-01-01 2023-03-31 xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure iso4217:CNY utr:sqm

Filing Compare · Longduoduo Co Ltd